Index

“t” following page number indicates table.

abdominal pain. See toxicity, abdominal pain
absolute neutrophil count (ANC): GOG 157, 39; GOG 132, 72
ACTION trial (Trimbos 2003b, Trimbos 2010), 1, 19, 23, 24–32, 43, 193, 197
Adjuvant Chemotherapy in Ovarian Neoplasm Trial. See ACTION trial
Adriamycin. See doxorubicin
Adriamycin + cyclophosphamide. See cyclophosphamide + doxorubicin/
Adriamycin (CA)
Adriamycin + cyclophosphamide + platinum. See cyclophosphamide + doxorubicin/
Adriamycin + platinum (CAP)
advanced-stage ovarian cancer, CA125 normalization: OV16, 143t; paclitaxel + carboplatin (TC), 143t
advanced-stage ovarian cancer, negative second look: cyclophosphamide +
cisplatin (CP), 56t; cyclophosphamide + doxorubicin + cisplatin (CAP), 52t;
cyclophosphamide + cisplatin (CP), 52t; GOG 52, 52t; GOG 97, 56t; measurable, 56t; non-measurable, 56t
advanced-stage ovarian cancer, overall survival: AGO/OVAR-3, 104t; AGO-
OVAR9, 136t; carboplatin, 69t, 94t; carboplatin + pegylated liposomal
doxorubicin (C-PLD), 130t; CHORUS, 183–185, 185t; cisplatin, 73t; clear cell
histology, 125t, 149t; cyclophosphamide + cisplatin (CP), 56t, 61t, 65t, 84t;
cyclophosphamide + doxorubicin (CA), 49t; cyclophosphamide + doxorubicin +
cisplatin (CAP), 49t, 52t, 69t; cyclophosphamide + cisplatin (CP), 52t;
Danish Netherlands Trial, 78t; dose-dense paclitaxel + carboplatin, 124t;
EORTC 55971, 177t; EORTC-GCG 55865, 167t; GOG 47, 49t; GOG 52, 52t;
GOG 97, 56t; GOG 104, 65t; GOG 111, 61t; GOG 114, 89t; GOG 132, 73t; GOG 152, 172t; GOG 158, 98t; GOG 172, 113t;
GOG 182/ICON5, 118t; GOG 218, 155t; high-risk group, 149t; ICON2, 69t;
ICON3, 94t; ICON7, 149t; interval debulking surgery, 167t, 172t; intraperitoneal cisplatin-based chemotherapy, 65t, 89t, 113t; JGOG 3016, 124t; low-grade serous histology, 149t; measurable
disease, 49t, 65t, 113t; MITO-2, 130t; mucinous histology, 125t; neoadjuvant chemotherapy, 177t, 185t; no interval debulking surgery, 167t, 172t; non-measurable disease, 49t; no visible residual disease, 113t; optimal, 124; optimal stage III, 189; OV-10, 84t; OV16, 143t; paclitaxel, 73t; paclitaxel + carboplatin (TC), 78t, 94t, 98t, 104t, 124t, 130t, 136t, 143t, 149t, 155t; paclitaxel +
carboplatin + bevacizumab (PCB), 149t,
advanced-stage ovarian cancer, overall survival (cont.)
- 155t; paclitaxel + cisplatin (TP), 61t, 73t, 78t, 84t, 89t, 98t, 104t, 113t; primary debulking, 177t, 185t; serous histology, 125t; stage IV, 189; suboptimal, 124t; suboptimal stage III, 189
advanced-stage ovarian cancer, pathologic complete response: cisplatin, 73t; cyclophosphamide + cisplatin (CP), 65t, 84t; GOG 104, 65t; GOG 132, 73t; GOG 158, 98t; GOG 172, 113t; intraperitoneal cisplatin-based chemotherapy, 65t, 113t; OV-10, 84t; paclitaxel, 73t; paclitaxel + carboplatin (TC), 98t; paclitaxel + cisplatin (TP), 73t, 84t, 98t, 113t; primary debulking, 177t, 185t; SCOTROC, 108t; serous histology, 124t; suboptimal, 124t; weekly paclitaxel + carboplatin, 160t
advanced-stage ovarian cancer, progression-free interval: carboplatin, 69t; cyclophosphamide + doxorubicin (CA), 49t; cyclophosphamide + doxorubicin + cisplatin (CAP), 49t, 52t, 69t; cyclophosphamide + cisplatin (CP), 52t, 84t; GOG 47, 49t; GOG 52, 52t; ICON2, 69t; OV-10, 84t; paclitaxel + cisplatin (TP), 84t
advanced-stage ovarian cancer, progression-free survival: AGO/OVAR-3, 104t; AGO-OVAR9, 136t; carboplatin, 94t; carboplatin + pegylated liposomal doxorubicin (C-P LD), 130t; CHORUS, 185t; cisplatin, 73t; clear cell histology, 125t; cyclophosphamide + cisplatin (CP), 56t, 61t; docetaxel + carboplatin, 108t; dose-dense paclitaxel + carboplatin, 124t; EORTC 55971, 177t; EORTC-GCG 55865, 167t; GOG 97, 56t; GOG 111, 61t; GOG 114, 89t; GOG 132, 73t; GOG 152, 172t; GOG 158, 98t; GOG 172, 113t; GOG 178/SWOG 9701, 190t; GOG 182/ICON5, 118t; GOG 218, 155t; high-risk group, 149t; ICON3, 94t; ICON7, 149t; interval debulking surgery, 167t, 172t; intraperitoneal cisplatin-based chemotherapy, 89t, 113t; JGOG 3016, 124t; maintenance paclitaxel, 190t; measurable disease, 113t; MITO-2, 130t; MITO-7, 160t; mucinous histology, 125t; neoadjuvant chemotherapy, 177t, 185t; no interval debulking surgery, 167t, 172t; no visible residual disease, 113t; optimal, 124t; OV16, 143t; paclitaxel, 73t; paclitaxel + carboplatin (TC), 94t, 98t, 104t, 108t, 124t, 130t, 136t, 143t, 149t, 155t, 160t; paclitaxel + carboplatin + bevacizumab (PCB), 149t, 155t; paclitaxel + cisplatin (TP), 61t, 73t, 89t, 98t, 104t, 113t; primary debulking surgery, 177t, 185t; SCOTROC, 108t; serous histology, 124t; suboptimal, 124t; weekly paclitaxel + carboplatin, 160t
advanced-stage ovarian cancer, RECIST response: AGO/OVAR-3, 104t; cisplatin, 73t; cyclophosphamide + cisplatin (CP), 56t, 61t; cyclophosphamide + doxorubicin (CA), 49t; cyclophosphamide + doxorubicin + cisplatin (CAP), 49t; Danish Netherlands Trial, 78t; GOG 47, 49t; GOG 97, 56t; GOG 111, 61t; GOG 132, 73t; OV16, 143t; paclitaxel, 73t; paclitaxel + carboplatin (TC), 78t, 104t, 143t; paclitaxel + cisplatin (TP), 61t, 73t, 78t, 104t
advanced-stage ovarian cancer, response duration: cyclophosphamide + doxorubicin (CA), 49t; cyclophosphamide + doxorubicin + cisplatin (CAP), 49t; GOG 47, 49t
advanced-stage ovarian cancer, response rate: AGO-OVAR9, 136t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t; cyclophosphamide + cisplatin (CP), 61t, 84t; Danish Netherlands Trial, 78t; docetaxel + carboplatin, 108t; dose-dense paclitaxel + carboplatin, 124t; GOG 111, 61t; ICON7, 149t; JGOG 3016, 124t; MITO-2, 130t; MITO-7, 160t; OV-10, 84t; OV16, 143t; paclitaxel + carboplatin (TC), 78t, 108t, 124t, 130t, 136t, 143t, 149t, 160t; paclitaxel + carboplatin + bevacizumab (PCB), 149t; paclitaxel + cisplatin (TP), 61t, 78t, 84t; SCOTROC, 108t; weekly paclitaxel + carboplatin, 160t
age, prognostic factor, 52, 64
AGO. See Arbeitsgemeinschaft Gynakologische Onkologie
AGO-OVAR-3 (du Bois 2003), 46, 91, 99, 100–105, 223
AGO-OVAR-9 (du Bois, 2010), 46, 132–137
Index

AGO-OVAR/NCIC/EORTC (Pfister 2006a), 115, 133, 200, 222–228, 242, 243, 249, 251, 255–256
alkylating agent and risk of leukemogenesis, 48
allergic reaction. See toxicity, allergic
reaction
alopecia. See toxicity, alopecia
altretamine, FDA approval, 235
ALZA Corp, 207
analysis of covariance, CHORUS, 183
analysis of variance: AGO-OVAR/NCIC/ EORTC trial, 227; Doxil Study 30–49, 212
anaphylaxis. See toxicity, anaphylaxis
anemia. See toxicity, anemia
angiogenesis, 145, 151
anorexia. See toxicity, anorexia
antibiotics, SCOTROC, 107
antiemetic regimens: AGO-OVAR-3, 102; CALYPSO, 245; GICOG trials, 11; SCOTROC, 107
ANZGOG. See Australia and New Zealand Gynecologic Oncology Group
Arbeitsgemeinschaft Gynakologische Onkologie (AGO), 100, 132, 145, 217, 222, 243
area under the curve (AUC): Calvert formula, 33, 68, 76, 87, 91, 96, 101, 107, 120–121, 128, 133, 158, 195, 218, 244; pegylated liposomal doxorubicin, 208
arterial thrombosis. See toxicity, arterial
thrombosis
arthralgia. See toxicity, arthralgia
ascertainment bias, 37
ascites: AURELIA, 260, 262; prognostic
significance, 17
Asian ethnicity, survival differences, 125
assessable disease: AGO-OVAR/NCIC/ EORTC trial, 223; Doxil Study 30–49, 209; gemcitabine versus PLD trial, 230; unidimensional, 209
assessment methods: ACTION, 21; GOG 47, 48; ICON1, 21
assessment schedule: AGO-OVAR-3, 102–103; AGO-OVAR9, 134; AGO-OVAR/NCIC/EORTC trial, 224; AURELIA, 259; CALYPSO, 245; CHORUS, 181; Danish Netherlands Trial, 77; Doxil Study 30–49, 211; EORTC 55971, 175; EORTC-GCG 55865, 165; gemcitabine versus PLD trial, 230; GICOG trials, 12; GOG 52, 51; GOG 97, 55; GOG 111, 59; GOG 114, 88; GOG 132, 72; GOG 152, 170; GOG 157, 40; GOG 158, 97; GOG 172, 111; GOG 175, 196; GOG 178/SWOG 9701, 188–189; GOG 218, 153; ICON1, 34, 37; ICON2, 68; ICON3, 92; ICON4/AGO-OVAR 2.2, 219; ICON7, 146; JGOG 3016, 122; MITO-2, 128, 129; MITO-7, 159; OCEANS, 252, 255; OV-10, 83; OV16, 140, 141; OVA-301, 238; SCOTROC, 107–109
atrioventricular block, 60
AURELIA (Pujade-Lauraine 2014), 200, 256–262
Australia and New Zealand Gynecologic Oncology Group, 114, 145, 243
autologous bone marrow rescue, 57
Aventis Pharmaceuticals, 105
barium enema: EORTC 55971, 174; GICOG trials, 11; GOG 7601, 3; GOG 7602, 6; OV16, 138
benzodiazepines, 11
bevacizumab: activity in ovarian cancer, 145, 151, 249, 257, 262; activity in platinum-resistant recurrent ovarian cancer, 257, 260; activity in platinum-sensitive recurrent ovarian cancer, 253; angiogenesis, 151; arterial thrombosis, 153; benefit with increased disease severity, 150; BOOST trial, 150; bowel perforation, 150, 153; breast cancer, 150, 151; coagulopathy, 153; colon cancer, 150, 151, 262; combined with carboplatin and gemcitabine, 251; combined with metronomic cyclophosphamide, 250; combined with paclitaxel weekly, 258; combined with pegylated liposomal doxorubicin, 258; combined with topotecan, 258; convergence of survival curves, 156; cost-effectiveness, 151; dose adjustment for weight change, 153; dose duration, 156; dose modifications, 252; dose selection, 156; durable benefit, 150; duration of response, 250; exclusion criteria, 251, 257–258; fistula, 250;
bevacizumab (cont.)
gastrointestinal perforation, 250, 255, 257–258, 262; GOG 218, 151–157; hypersensitivity, 153; ICON7, 145–151; hypertension, 150, 153; intestinal obstruction, 153; maintenance therapy, 146, 152, 157, 252; monoclonal antibody, 145, 151, 249, 257; phase II results, 249; proteinuria, 255; regrowth of tumor, 156; response rate, 250, 255; reversible posterior leukoencephalopathy syndrome, 153, 255; proteinuria, 153; timing from surgery, 251; timing of maximum impact, 148; venous thrombosis, 153; wound healing, 146, 153, 251
bilirubin. See toxicity, bilirubin
biologic progression-free interval, ICON7, 147
biomarkers, ICON7, 151
bleeding. See toxicity, bleeding
Blyth-Still-Casella method, AGO-OVAR9, 135
bone marrow function: AGO-OVAR-3, 101; AGO-OVAR9, 133; AGO-OVAR/NCIC/EORTC trial, 223; Danish Netherlands Trial, 75; Doxil Study 30–49, 209; GOG 97, 54; GOG 111, 58; GOG 114, 87; GOG 132, 71; GOG 152, 169; GOG 158, 96; GOG 175, 196; GOG 182/ICONS, 115; JGOG 3016, 120; MITO-7, 158; OV-10, 81; OV16, 138; OVA-301, 236; topotecan versus paclitaxel study, 202
borderline ovarian tumors: inclusion in trial, 5, 9; indolent course, 5
bowel obstruction. See toxicity bowel obstruction
bowel perforation. See gastrointestinal perforation
bowl resection, CHORUS, 181
bradyarrhythmias, 60
Breslow tests for significance, Danish Netherlands Trial, 77
Bristol-Meyers Squibb, 75
Brookmeyer-Crowley method, OCEANS, 253
CA. See cyclophosphamide + doxorubicin/Adriamycin
CA125: assessable disease, 230, 244; AURELIA, 257, 259; CALYPSO, 244, 245; criteria for disease progression, 122, 141, 171; CHORUS, 181, 182; Danish Netherlands Trial, 77, 79; Doxil Study 30–49, 209; EORTC-GCG 55865, 165; GCIG criteria, 153, 244, 245, 257, 259; gemcitabine versus PLD trial, 229, 230; GICOG, 12; GOG 97, 55; GOG 104, 63; GOG 132, 72; GOG 152, 170; GOG 172, 111; GOG 175, 196; GOG 178/SWOG 9701, 187; GOG 182/ICONS, 117; GOG 218, 153; ICON4/AGO-OVAR 2.2, 218, 219; ICON7, 148; JGOG 3016, 122; MITO-7, 159; normalization as endpoint, 144; OCEANS, 252; OV-10, 83; OV16, 140; OV16, 141; prognostic factor, 233, 248; Rustin method, 107, 153–154, 230; SCOTROC, 107–109; sign of progressive disease, 79; surrogate for outcome, 83, 144
CA125 normalization in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, CA125 normalization
CA125 progression in recurrent ovarian cancer. See recurrent ovarian cancer, progression by CA125
CA125 response in recurrent ovarian cancer. See recurrent ovarian cancer, response by CA125 criteria
CA125 to CEA ratio: CHORUS, 179; EORTC 55971, 174; JGOG 3016, 120; OV16, 138
Calvert formula: AGO-OVAR-3, 101; AGO-OVAR9, 133; CALYPSO, 244; Danish Netherlands Trial, 76; GOG 114, 87; GOG 158, 96; GOG 175, 195; ICON1, 33; ICON2, 68; ICON3, 91; ICON4/AGO-OVAR 2.2, 218; JGOG 3016, 120, 121; MITO-2, 128; MITO-7, 158; SCOTROC, 107
CALYPSO (Pujade-Lauraine 2010), 200, 242–249, 249, 255–256
cancer-specific survival, definition, 29
cancer-specific survival in high-risk early-stage ovarian cancer. See early-stage ovarian cancer, high-risk, cancer-specific survival
CAP. See cyclophosphamide + doxorubicin/Adriamycin + platinum (CAP)
carboplatin: ACTION, 21, 27; AGO-OVAR/NCIC/EORTC trial, 223; AUC 2, 158;
Index

AUC 4, 224; AUC 5, 33, 68, 76, 107, 128, 115, 128, 133, 139, 146, 223, 244, 251; AUC 6, 99, 101, 116, 120, 121, 152, 158, 195; AUC 7, 107; AUC 7.5, 39, 96, 99; AUC 9, 86, 90; Calvert formula, 76, 91, 96, 101, 107, 120, 121, 134, 158, 195, 218, 224, 244, 251; Cockcroft-Gault formula, 68, 128, 139, 158, 219, 244; combination regimens, 33; dose, 99; dose reduction, 224; dose reduction for GFR method, 68; early-stage ovarian cancer, 20, 25, 33; equivalence to CAP, 68; equivalence to cisplatin, 66, 91, 95, 103; FDA approval, 235; first-line treatment, 95; hypersensitivity reaction, 246, 248; ICON1, 21; ICON2, 68, 91; ICON3, 91, 100; ICON4/AGO-OVAR 2.2, 218; inferior to cisplatin, 75; Jelliffe method, 87, 96, 101, 121, 134, 195, 224; less toxicity than cisplatin, 67, 75, 99, 100, 103, 105; maximum tolerated dose, 101; neurotoxicity, 99; platinum-sensitive ovarian cancer, 222, 243; preferred agent in early-stage ovarian cancer, 24, 37; progression-free survival, 225; recommendation against upfront use, 96; SCOTROG, 107; substitution for cisplatin, 82; toxicity, 95; use in United Kingdom, 67; weekly administration, 161

carboplatin + docetaxel. See docetaxel + carboplatin
carboplatin + gemcitabine: AGO-OVAR/NCIC/ECOG/NCIC, 222–228, 242, 243; approval in Europe, 249; approval in United States, 249; combined with bevacizumab, 251; dose reduction, 224; OCEANS, 251; platinum-sensitive ovarian cancer, 227; progression-free survival, 225, 249; response rate, 223

carboplatin + paclitaxel. See paclitaxel + carboplatin (TC)
carboplatin + pegylated liposomal doxorubicin (PLD): alternative front-line therapy, 131; CALYPSO, 244, 249; duration of therapy, 249; MITO-2, 126–132; overall survival, 244, 249; platinum-sensitive ovarian cancer, 249; progression-free survival, 244; response rate, 243–244; superior to carboplatin alone, 249; toxicity profile, 131

cardiac function: Doxil Study 30–49, 209; OVA-301, 236, 238
cardiac ischemia. See toxicity, cardiac ischemia
cardiac toxicity. See toxicity, cardiac
central nervous system bleeding. See toxicity, central nervous system bleeding
chemical tumor debulking, 86
chemoresistance: early-stage ovarian cancer, 42; influence on survival, 137; time to treatment failure, 137
chemotherapy, superiority of combination regimens, 66
chest radiography: Doxil Study 30–49, 211; GICOG trials, 11, 12; GOG 152, 170; GOG 178/SWOG 9701, 187; GOG 7601, 3; GOG 7602, 6
Chi-square test: ACTION, 29; CALYPSO, 246; ICON1/ACTION, 21, 23; ICON3, 92; ICON4/AGO-OVAR 2.2, 220; JGOG 3016, 123; MITO-2, 131; OVL0, 83; test for interaction, 92; test for trend, 92
cimetidine, 39, 76, 88, 96, 102, 106, 196
cisplatin: ACTION, 21, 26; dose adjustment, 71; dosing, 11, 33, 71; efficacy, 47; equivalence to carboplatin, 66, 91; equivalence to PC (paclitaxel + cisplatin), 74; FDA approval, 235; GICOG trials, 11; GOG 132, 70; higher dose in GOG 132, 71; ICON4/AGO-OVAR 2.2, 219; immediate versus delayed treatment, 13–14; intraperitoneal, 63, 86, 88; renal monitoring, 48, 51; superiority of, 12, 20, 48; toxicity, 99
cisplatin + cyclophosphamide. See cyclophosphamide + cisplatin (CP)
cisplatin + cyclophosphamide + doxorubicin/Adriamycin. See cyclophosphamide + doxorubicin/Adriamycin + platinum (CAP)
cisplatin + doxorubicin/Adriamycin + cyclophosphamide. See cyclophosphamide + doxorubicin/Adriamycin + platinum (CAP)
cisplatin + paclitaxel. See paclitaxel +
cisplatin (TP)
clear cell histology: no benefit with
dose-dense paclitaxel administration,
123; poor response to chemotherapy, 199;
prognostic factor, 2, 17; response rate to
chemotherapy, 44–45; worse outcomes,
5, 9, 52
clemastine, 102
clinical response rate, GOG 97, 57
clinical trials limitations, 235
cogulopathy: bevacizumab, 153; GOG
123; poor response to chemotherapy, 199;
prognostic factor, 2, 17; response rate to
chemotherapy, 44–45; worse outcomes,
5, 9, 52
computerized tomography (CT) scan: AGO-
OVAR-3, 103; AURELIA, 259;
CALYPSO, 245; CHORUS, 181; Danish
Netherlands Trial, 77; Doxil Study
30–49, 211; GOG 47, 48; EORTC-GCG
55865, 165; topotecan versus paclitaxel
trial, 203
cumulative incidence, 12
cutaneous toxicity. See toxicity, skin
cyclophosphamide: alkylating agent, 48; dose modifications, 59; hemorrhagic cystitis, 55; maintenance therapy in GOG 47, 47, 48; metronomic, 250
cyclophosphamide + cisplatin (CP): disease control rate with, 57, 58; dose modifications, 82; EORTC-GCG 55865, 164; equivalence to cyclophosphamide + doxorubicin/Adriamycin + platinum (CAP), 100; GOG 52, 51, 100; GOG 95, 9, 15, 16; GOG 97, 53; GOG 104, 63; GOG 111, 58, 80, 100; GOG 114 arm discontinued, 87; inferiority compared to single-agent platinum, 95; intensive intravenous dosing, 54; intraperitoneal dosing, 63; OV-10, 80, 81, 100; possible antagonistic effect, 74; standard intravenous dosing, 54; standard of care, 57, 201; superiority of, 17; toxicity of, 56
cyclophosphamide + doxorubicin/Adriamycin (CA): GOG 47, 47; subsequent treatment with cisplatin, 49–50

cyclophosphamide + doxorubicin/Adriamycin + platinum (CAP): first line treatment, 95; GOG 47, 47, 48, 100; GOG 52, 51; ICON1, 21, 33; ICON2, 36, 67, 91; ICON3, 92, 100; lower cyclophosphamide dose than in CA regimen, 52; superiority over cyclophosphamide + doxorubicin, 48, 50, 100; superiority over cyclophosphamide + cisplatin, 66–67; toxicity, 70; use in Italy, 67
cystectomy (bladder), CHORUS, 181
cytoreductive surgery: drug-resistant clones, 163; EORTC-GCG 55865, 162–168; rationale, 163; tumor growth rate, 163

Danish Netherlands trial (Neijt 2000), 46, 75–79, 91, 99, 105
death due to treatment. See toxicity, death due to treatment
delay in treatment: AGO-OVAR-3, 102; AGO-OVAR/NCIC/EORTC trial, 224; CALYPSO, 245; gemcitabine versus PLD trial, 230; GOG 104, 63; GOG 111, 59; GOG 132, 72; GOG 157, 39; GOG 158, 96–97; GOG 172, 111; GOG 175, 196; GOG 178/SWOG 9701, 188; GOG 182/ICON5, 117; JGOG, 121; MITO-2, 128; OCEANS, 252; OV16, 139; OVA-301, 241; SCOTROC, 107
dermatologic toxicity. See toxicity, skin
dexamethasone, 11, 39, 59, 70, 81, 88, 96, 102, 106, 196, 203, 237
diaphragm stripping, CHORUS, 181
diarrhea. See toxicity, diarrhea
diphenhydramine, 39, 59, 76, 81, 88, 96, 106, 196
disease control rate in recurrent ovarian cancer. See recurrent ovarian cancer, disease-control rate
disease-free survival in high-risk early-stage ovarian cancer. See early-stage ovarian cancer, high-risk, disease-free survival
disease-free survival in low-risk early-stage ovarian cancer. See early-stage ovarian cancer, low-risk, disease-free survival
disease-free survival in stage I ovarian cancer. See stage I ovarian cancer, disease-free survival
docetaxel: activity in ovarian cancer, 105; combination with carboplatin, 105, 106, 109; dexamethasone treatment, 106; dose, 106; dose discontinuation, 107; dose reduction, 106, 107; hypersensitivity reaction, 107; substitution for paclitaxel, 152
docetaxel + carboplatin, 105–109
dose-dense paclitaxel: antiangiogenic effect, 123; hematologic toxicity, 123; improved survival, 123; rationale, 123
dose escalation: GOG 47, 48; GOG 52, 51; topotecan versus paclitaxel trial, 203
dose intensity: GOG 97, 54; GOG 114, 88; GOG 157, 39; no impact on outcome, 57, 126; topotecan versus paclitaxel trial, 203
dose reduction: AGO-OVAR-3, 102; AGO-OVAR9, 133, 134; AGO-OVAR/NCIC/EORTC trial, 224; AURELIA, 259; CALYPSO, 245; Danish Netherlands Trial, 76; Doxil Study 30–49, 210, 214t; gemcitabine versus PLD trial, 230; GOG 47, 47–48; GOG 52, 51; GOG 97,
dose reduction (cont.)
54; GOG 157, 39; GOG 158, 96; GOG 172, 111; GOG 175, 196; GOG 178/
SWOG 9701, 188; GOG 182/ICON5, 117;
JGOG 3016, 206; MITO-2, 128; MITO-7, 128; OVA-301, 237;
pegylated liposomal doxorubicin, 210;
SCOTROC, 106–107; topotecan, 210;
topotecan versus paclitaxel trial, 203,
207
Doxil study 30–49 (Gordon 2001, Gordon 2004), 115, 200, 207–217, 234, 242, 243,
256
doxorubicin (Adriamycin): alopecia, 127;
cardiac toxicity, 127; congestive heart
failure, 48, 51; cumulative dose, 48, 51;
dose-limiting toxicity, 127; first-line
treatment, 126; gastrointestinal toxicity,
127; improved survival, 126, 132; lack of
treatment benefit, 50, 52; myelosuppres-
sion, 127; toxicity, 48, 208
doxorubicin + cyclophosphamide. See
cyclophosphamide + doxorubicin/
Adriamycin (CA)
doxorubicin + cyclophosphamide + platinum.
See cyclophosphamide + doxorubicin/
Adriamycin + platinum (CAP)
duration of chemotherapy, 38
duration of response in recurrent ovarian
cancer. See recurrent ovarian cancer,
duration of response
dyspnea. See toxicity, dyspnea
early-stage ovarian cancer: GOG 7601, 1–5;
prevalence, 37; recurrence risk, 17, 25,
32, 37, 38, 42, 43, 194
early-stage ovarian cancer, high-risk: GCIG
consensus recommendations, 194;
GICOG trials, 9–15; GOG 7602, 5–9;
recurrence risk, 7, 17, 36; survival, 7, 36
early-stage ovarian cancer, high-risk,
cancer-specific survival: ACTION, 29t,
31t; grade 3 tumors, 31t; no further
therapy, 29t, 31t; non-optimally staged,
29t, 31t; optimally staged, 29t, 31t;
platinum-based chemotherapy, 29t, 31t
early-stage ovarian cancer, high-risk,
disease-free survival: cisplatin, 14t;
GICOG trial 2, 14t; GOG 157, 42;
intraperitoneal $^{32}$P, 14t
early-stage ovarian cancer, high-risk,
overall survival: ACTION, 28t; by
histology, 45t; carboplatin + paclitaxel,
41t; cisplatin, 14t; cyclophospha-
mide + cisplatin (CP), 18t; GICOG trial 2,
14t; GOG 95, 18t; GOG 157, 41t; GOG
175, 198t; GOG 7602, 8t; ICON1, 35t;
ICON1/ACTION, 22t; intraperitoneal $^{32}$P,
8t, 14t, 18t; maintenance chemotherapy,
198t; melphalan, 8t; no further therapy,
22t, 28t, 35t; non-optimally staged, 28t;
non-serous histology, 45t; optimally
staged, 28t; paclitaxel + carboplatin (TC),
41t; platinum-based chemotherapy, 22t,
28t, 35t; serous histology, 45t
early-stage ovarian cancer, high-risk,
recurrence-free survival: ACTION, 28t,
29t, 31t; by ascites, 45t; by cytology, 45t;
by grade, 45t; by histology, 45t; by
performance status, 45t; by stage, 45t; by
tumor rupture, 45t; GOG 157, 45t; grade
3 tumors, 31t; ICON1, 35t; ICON1/
ACTION, 22t; no further therapy, 22t, 28t,
29t, 31t, 35t; non-optimally staged, 28t,
29t, 31t; non-serous histology, 45t;
onlymphatically staged, 28t, 29t, 31t;
platinum-based chemotherapy, 22t, 28t,
29t, 31t, 35t; serous histology, 45t
early-stage ovarian cancer, high-risk,
recurrence rate: ACTION, 28t, 29t;
carboplatin + paclitaxel, 41t; complete
staging, 41t; cyclophosphamide + cispla-
tin (CP), 18t; GOG 95, 18t; GOG 157, 41t;
GOG 158, 100; GOG 175, 198t;
intraperitoneal $^{32}$P, 18t; maintenance
chemotherapy, 198t; no further therapy,
28t, 29t; paclitaxel + carboplatin (TC),
41t; platinum-based chemotherapy, 28t,
29t; stage I, 42; stage II, 42; stage III, 100
early-stage ovarian cancer, low-risk:
cisplatin in, 15; definition, 5, 10; GICOG
trials, 9–15; GOG 7601, 1–5; 25; no
further treatment, 5, 10, 25
early-stage ovarian cancer, low-risk,
disease-free survival: cisplatin, 13t;
GICOG trial 1, 13t; GOG 7601, 4t;
melphalan, 4t; no further treatment, 4t, 13t
early-stage ovarian cancer, low-risk,
overall survival: cisplatin, 13t; GICOG trial 1,
13t; no further treatment, 13t
early termination of trial: federal mandate, 192; GOG 178/SWOG 9701, 189–190, 191, 192
Eastern Cooperative Oncology Group (ECOG), 86
echocardiogram, 211
ECOG. See Eastern Cooperative Oncology Group
Ecteinascidia turbinata, 235
electrocardiography: CALYPSO, 245; GOG 152, 170
Eli Lilly & Co, 228
endpoints: adverse events, 122, 141, 175; biologic progression-free interval, 147; CA125 as surrogate for outcome, 83, 144, 182; CA125 normalization at three cycles, 144; clinical response rate, 83, 171; complications, 117; cost-effectiveness, 83; cumulative dose delivery, 117; disease control rate, 231; dose intensity, 117; duration of response, 204, 212, 225, 239, 252; endorsed by AACR, 235; endorsed by ASCO, 235; endorsed by FDA, 235; endorsed by GCIG, 157; FACT-O/TOI score, 159; five-year survival, 68; health economics, 147; laboratory results, 147; negative second look, 53; non-standardized, 235; objective response rate, 159; overall response rate, 239, 252, 259; overall survival, 12, 21, 27, 34, 55, 60, 68, 72, 83, 88, 92, 97, 103, 109, 112, 117, 122, 129, 134, 141, 147, 159, 165, 171, 175, 182, 189, 196, 212, 219, 225, 228, 231, 238, 252, 259; pathologic response rate, 63, 90; performance status, 147; progression-free interval, 53, 55, 68, 153; progression-free survival, 60, 72, 77, 83, 88, 92, 97, 103, 109, 112, 117, 122, 129, 135, 141, 147, 153, 159, 165, 171, 175, 182, 189, 219, 225, 231, 238, 246, 252, 259; proportion without progression, 103; quality of life, 83, 103, 109, 112, 129, 135, 147, 175, 182, 219, 225, 239, 259; recurrence-free survival, 21, 27, 34; recurrence rate, 40, 196; relapse-free survival, 12; response rate, 48, 55, 72, 122, 137, 204, 212; response to treatment, 103, 135, 147, 225; safety, 212, 239, 259; surrogate, 235; survival, 2, 7, 53, 63, 68, 137, 204; time at risk of recurrence, 40; time to progression, 212; time to recurrence, 196, 204; time to response, 204, 212; time to treatment failure, 137; tolerability, 259; toxicity, 103, 117, 129, 135, 147, 159, 212, 225; translational research, 147; treatment activity, 129
ENGOT. See European Network of Gynaecological Oncological Trial Group
EORTC. See European Organization of Research and Treatment in Cancer
EORTC 55971 (Vergote 2010), 162, 174–178, 182
EORTC-GCG 55865 (van der Burg 1995), 162, 162–168, 168, 171, 173
epogen, 136t
eritropoietin, 145t, 214t
ethylenediaminetetraacetic acid (EDTA) clearance, Danish Netherlands Trial, 76
etoposide: lack of cross-resistance to platinum and taxanes, 208; response rates, 215; second-line therapy, 201
European Network of Gynaecological Oncological Trial Group (ENGOT), 157, 256
European Organization of Research and Treatment in Cancer (EORTC), 19, 24, 80, 138, 163, 174, 222, 243
exact linear rank test, MITO-2, 131
fatigue. See toxicity, fatigue
febrile neutropenia. See toxicity, febrile neutropenia
fever. See toxicity, fever
F. Hoffmann-La Roche, 256
filgrastim, GOG 157, 39
fine needle aspiration, EORTC 55971, 174
Fisher’s exact test: gemcitabine versus PLD trial, 231; GOG 104, 64; GOG 218, 154; JGOG 3016, 123; MITO-2, 131; OV-10, 83; OV16, 142
fistula. See toxicity, fistula
flexible parametric survival models, ICON7, 148
Food and Drug Administration, approval of pegylated liposomal doxorubicin, 208
Freedman’s method for sample size calculation, gemcitabine versus PLD trial, 231
Functional Assessment of Cancer Therapy—Gynecologic Oncology Group—Ntx, MITO-7, 159
Functional Assessment of Cancer Therapy—Ovarian (FACT-O) questionnaire: GOG 172, 111; GOG 218, 153, 154; MITO-7, 159, 160t; primary endpoint, 159

Functional Living Index—Cancer (FLIC), GOG 97, 55
gastrointestinal perforation. See toxicity, gastrointestinal perforation
gastrointestinal toxicity. See toxicity, gastrointestinal
gastroscopy: EORTC 55971, 174; OV16, 138
GCIG. See Gynecologic Cancer Intergroup
GCIG criteria for CA125 response, 153, 244, 245, 257, 259
GEICO. See Grupo de Investigacion de Cancer De Ovario
gemcitabine: combination regimens, 223–224, 229, 251; combined with paclitaxel and carboplatin, 116–117, 132–137; dose modifications, 252; dose reduction, 224; dosing, 230; FDA approval, 235; front-line chemotherapy, 116–117, 132–137; gemcitabine versus PLD trial, 228–234; fatigue, 137; hematoologic toxicity, 137; lack of cross-resistance to platinum and taxanes, 208; nucleoside analogue, 223; phase II studies, 229; platinum-resistant ovarian cancer, 229; recurrent ovarian cancer, 115, 132, 133, 223, 243; response rates, 215
gemcitabine + carboplatin. See carboplatin + gemcitabine
Gemcitabine versus PLD trial (Mutch 2007), 132, 200, 228–234, 256
Gemzar. See gemcitabine
Genentech, 249

genitourinary toxicity. See toxicity, genitourinary
GICOG trials (Bolis 1995), 1, 9–15, 19, 20, 24, 25, 32, 36, 38, 193, 197
GINECO. See Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens
global deterioration of health, GOG 218, 154
global test of heterogeneity, GICOG trials, 12
glomerular filtration rate (GFR): 24-hour urine collection, 218; edetic acid, 107; equivalent to creatinine clearance, 87; GOG 114, 87; ICON1, 33; ICON2, 68; nuclear renogram, 139; peroxidase-antiperoxidase method can result in excessive dosing, 125; radioisotope method, 218; SCOTROC, 107
GOG. See Gynecologic Oncology Group
GOG 47 (Omura 1986), 46, 46–50, 50, 100
GOG 52 (Omura 1989), 46, 50–53, 100
GOG 95 (Young, 2003), 1, 15–19, 38, 193, 197
GOG 97 (McGuire 1995), 46, 52–57
GOG 104 (Alberts 1996), 46, 62–66, 90, 110, 189
GOG 111 (McGuire 1996), 38, 46, 57–62, 66, 70, 74, 80, 83, 85, 87, 90, 91, 95, 100, 105, 189, 191, 194, 201, 208
GOG 114 (Markman 2001), 46, 86–90, 110
GOG 132 (Muggia 2000), 46, 70–74, 91, 95, 189, 191
GOG 152 (Rose 2004), 162, 168–173, 175
GOG 157 (Bell 2006, Chan 2007), 1, 37–45, 193, 194, 197, 199
GOG 158 (Ozols 2003), 46, 91, 95–100, 194
GOG 172 (Armstrong 2006), 46, 90, 109–114
GOG 175 (Mannel 2011), 186, 193–199
GOG 178/SWOG 9701 (Markman 2003), 186, 186–193, 194, 195
GOG 182/ICON5 (Bookman 2009), 46, 100, 114–119, 120, 137, 142
GOG 218 (Burger 2011), 46, 150, 151–157, 262
GOG 7601 (Young 1990), 1, 15, 20, 23, 25, 36, 37, 193
GOG 7602 (Young 1990), 1, 5–9, 32, 38, 42, 193, 197

grade, prognostic factor, 2, 30, 52
Grambsch-Therneau test, CHORUS, 183
granulocyte colony-stimulating factors (G-CSFs): AGO-OVAR-3, 102; AGO-OVAR9, 134, 136; Doxil Study 30–49, 210, 214t; gemcitabine versus PLD trial, 230; GOG 132, 72; GOG 152, 169; GOG 158, 96–97; GOG 172, 111; GOG 175, 196; GOG 178/SWOG 9701, 188; GOG 182/ICON5, 117; GOG 218, 152; JGOG 3016, 121; OV-10, 82; OV16,
Index

145t; OVA-301, 237, 240t; SCOTROC, 107; topotecan versus paclitaxel trial, 203, 206t, 207.

granulocyte count, prognostic impact, 79
granulocyte macrophage colony-stimulating factors (GM-CSFs), AGO-OVAR9, 134
granulocyte toxicity. See toxicity, granulocyte

Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), 127, 132, 145, 243
Grupo de Investigacion de Cancer De Ovario (GEICO), 138, 145
Gynecologic Cancer Intergroup (GCIG), 132, 138, 141, 145, 157, 256
Gynecologic Oncology Group (GOG), 1, 5, 15, 37, 46, 50, 53, 57, 62, 70, 86, 95, 110, 114, 151, 168, 187, 193

hand-foot syndrome. See toxicity, palmar-plantar erythrodysesthesia (PPE)
hazard functions, ICON7, 148
hazard ratio, pooled, 23
hearing loss. See toxicity, ototoxicity
heart block. See toxicity, heart block
hematologic function. See bone marrow function
hematologic parameters to treat: AGO-OVAR9, 134; dose-dense paclitaxel, 121; JGOG 3016, 121; MITO-2, 128; OV16, 139
hematologic toxicity. See toxicity, hematologic
hemoglobin, prognostic impact, 79
hemorrhagic cystitis. See toxicity, hemorrhagic cystitis
hepatic function: AGO-OVAR-3, 101; AGO-OVAR9, 133; Danish Netherlands Trial, 76; Doxil Study 30–49, 209; GOG 97, 54; GOG 111, 58, GOG 114, 87; GOG 132, 71; GOG 152, 169; GOG 158, 96; GOG 182/ICONS, 115; JGOG 3016, 120; OV-10, 81; OVA-301, 236; topotecan versus paclitaxel study, 202
hepatic toxicity. See toxicity, hepatic
heterogeneity: statistical, 24, 42, 131; tumors, 44
hexamethylmelamine: response rates, 215; second-line therapy, 201
high-dose chemotherapy with stem cell support, treatment option for recurrent ovarian cancer, 215
histamine H1 antagonist, 203
histamine H2 antagonist, 59, 203
histology, prognostic impact, 178
homogeneity, statistical, 44, 55, 60
hormonal therapy, treatment option for recurrent ovarian cancer, 215
hospitalization. See toxicity, hospitalization
Hyacamtn. See topotecan
hydration regimens: cyclophosphamide + cisplatin (CP), 81; GICOG trials, 11; paclitaxel + cisplatin (TP), 82
hypersensitivity. See toxicity, hypersensitivity
hypertension. See toxicity, hypertension
Hy’s law, 241

ICON. See International Collaborative Ovarian Neoplasm
ICON1 (Colombo 2003), 1, 19, 23, 24, 32–37
ICON1/ACTION combined analysis (Trimbos 2003a), 1, 19–24, 42, 193, 197
ICON2 (Lancet 1998), 36, 46, 66–70, 91
ICON3 (Lancet 2002), 46, 70, 90–95, 185
ICON4/AGO-OVAR 2.2 (Parmar 2003), 200, 216, 217–221, 222, 242, 243, 246, 249, 255–256
ICON7 (Perrin 2011, Oza 2015), 46, 145–151, 156, 262
ifosfamide: response rates, 215; second-line therapy, 201
immunologically active subtype of ovarian cancer, ICON7, 151
inclusion criteria, more than one prior chemotherapy regimen allowed: CALYPSO, 244; gemcitabine versus PLD trial, 229; ICON4/AGO-OVAR 2.2, 218
inclusion criteria, one prior chemotherapy regimen allowed: Doxil Study 30–49, 209; ICON4/AGO-OVAR 2.2, 218; OVA-301, 236; topotecan versus paclitaxel trial, 202
inclusion criteria, stage I ovarian cancer: AGO-OVAR9, 133; GOG 175, 195; ICON2, 69; high-risk, 2, 6; ICON7, 146; low-risk, 2, 6; MITO-2, 127; MITO-7, 158; SCOTROC, 106
inclusion criteria, stage II ovarian cancer: AGO-OVAR-3, 101; AGO-OVAR9, 133; Danish Netherlands Trial, 75; EORTC-GCG 55865, 164; GOG 175, 195; ICON2, 69; ICON7, 146; JGOG 3016, 120; MITO-2, 127; MITO-7, 158; OV-10, 80; OV16, 138; SCOTROC, 106
inclusion criteria, stage III ovarian cancer: AGO-OVAR-3, 101; AGO-OVAR9, 133; CHORUS, 179; Danish Netherlands Trial, 75; EORTC 55971, 174; EORTC-GCG 55865, 164; GOG 47, 47; GOG 52, 50; GOG 97, 54; GOG 104, 62; GOG 111, 58; GOG 114, 86; GOG 132, 71; GOG 152, 168; GOG 158, 96; GOG 172, 110; GOG 178/SWOG 9701, 187; GOG 182/ICON5, 115; GOG 218, 151; ICON2, 69; ICON7, 146; JGOG 3016, 120; MITO-2, 127; MITO-7, 158; OV-10, 80; OV16, 138; SCOTROC, 106; topotecan versus paclitaxel study, 202
inclusion criteria, stage IV ovarian cancer: AGO-OVAR-3, 101; AGO-OVAR9, 133; CHORUS, 179; Danish Netherlands Trial, 75; EORTC 55971, 174; EORTC-GCG 55865, 164; GOG 47, 47; GOG 52, 50; GOG 97, 54; GOG 104, 63; GOG 114, 110; GOG 172, 111; greater concentrations, 62, 110; improved survival, 112, 145; lower systemic exposure, 114; superiority over intravenous cisplatin, 64, 90; toxicity, 110, 112, 114; tumor penetration, 64
intraperitoneal cisplatin: after bowel resection, 114; capillary uptake, 112–114; GOG 104, 63, 110; GOG 114, 110; GOG 172, 111; greater concentrations, 62, 110; improved survival, 112, 145; lower systemic exposure, 114; superiority over intravenous cisplatin, 64, 90; toxicity, 110, 112, 114; tumor penetration, 64
intraperitoneal paclitaxel: GOG 172, 111; intraperitoneal clearance, 114; toxicity, 114
intravenous pyelography, 3, 6, 11
Japanese Gynecologic Oncology Group (JGOG), 119
Japanese Gynecologic Oncology Group (JGOG), 119
Jelliffe method: AGO-OVAR-3, 101; AGO-OVAR9, 133; GOG 114, 87; GOG 158, 96; GOG 175, 195; JGOG 3016, 120
JGOG. See Japanese Gynecologic Oncology Group
JGOG 3016 (Katsumata 2009, Katsumata 2013), 46, 119–126, 159, 194
Johnson & Johnson, 235
Kaplan and Meier test: ACTION, 21, 27; ACTION/ICON combined analysis, 23; AGO-OVAR9, 135; AGO-OVAR/NCIC/EORTC trial, 227; CALYPSO, 246; Danish Netherlands Trial, 77; Doxil Study 30–49, 212; EORTC 55971, 176; EORTC-GCG 55865, 165; gemcitabine versus PLD trial, 231; GICO trials, 12;
Index

GOG 95, 17; GOG 97, 55; GOG 111, 60; GOG 114, 88; GOG 158, 97; GOG 172, 112; GOG 7601, 4; GOG 7602, 7; ICON4/AGO-OVAR 2.2, 220; inverted, 129; JGOG 3016, 123; ICON1, 21, 34; ICON2, 68; ICON3, 92; MITO-2, 129; OCEANS, 253; OV-10, 83; OVA-301, 239; topotecan versus paclitaxel trial, 204

Karnofsky index, 101

Kruskal-Wallis rank test: GOG 97, 57; GOG 111, 60; GOG 158, 97; OV-10, 83

left ventricular ejection fraction: CALYPSO, 245; Doxil Study 30–49, 209, 210, 211, 214; OVA-301, 236, 238

leukemia, 42, 48, 193

leukopenia. See toxicity, leukopenia

likelihood ratio test, 53

linear models: GOG 172, 112; GOG 218, 154

liposomes, 127, 208

liver function. See hepatic function

log-rank test: ACTION, 21, 27; AGO-OVAR9, 135; AGO-OVAR/NCIC/EORTC trial, 227; AURELIA, 260; CHORUS, 183; Danish Netherlands Trial, 77; Doxil Study 30–49, 212; EORTC 55971, 176; EORTC-GCG 55865, 165; gemcitabine versus PLD trial, 231; GICOG trials, 12; GOG 95, 55; GOG 111, 60; GOG 114, 88; GOG 152, 170; GOG 175, 197; GOG 7601, 4; GOG 7602, 7; ICON1, 21; ICON2, 68; ICON3, 92; ICON7, 147, 148; Mantel-Cox version, 34, 68, 92; MITO-2, 151; OCEANS, 253; OV-10, 83; OVA-301, 239; stratified, 34, 92, 117, 142, 183, 212, 239, 253, 260; unstratified, 83, 147, 260. See also Mantel-Cox log-rank test

low-grade serous ovarian cancer, poor response to chemotherapy, 199

luteinizing hormone-releasing hormone analogues, 234

lymphadenectomy: CHORUS, 181; prognostic impact, 14

lymphangiography, 3, 6, 11

magnesium sulfate, GOG 104, 63

magnetic resonance imaging (MRI): AGO-OVAR-3, 103; AURELIA, 259; CALYPSO, 245; CHORUS, 181; Doxil Study 30–49, 209, 211; GOG 218, 153; ICON7, 147; MITO-2, 129; OV16, 140; topotecan versus paclitaxel study, 202

maintenance therapy: accelerated recurrence after discontinuation, 192; definition, 186; data in non-ovarian malignancies, 187; optimal duration, 193

mammogram, EORTC 55971, 174

MaNGO. See Mario Negri Gynecologic Oncology

mannitol, GOG 104, 63

Mann-Whitney U test: GOG 114, 88; ICON4/AGO-OVAR 2.2, 220

Mantel-Cox log-rank test: ICON1, 34; ICON2, 68; ICON4/AGO-OVAR 2.2, 220. See also log-rank test

Mantel-Haenszel Chi-square test: GOG 52, 52; GOG 97, 57

Mario Negri Gynecologic Oncology (MaNGO), 243

measurable ovarian cancer: AGO-OVAR/NCIC/EORTC trial, 223; AURELIA, 257; bidimensional, 209; CALYPSO, 244; Doxil Study 30–49, 209; gemcitabine versus PLD trial, 229, 230; GOG 97, 54, 55; OCEANS, 250; OVA-301, 236; prognostic factor, 248; topotecan versus paclitaxel study, 202

Medical Research Council (MRC), 32, 66, 91, 114, 145, 179, 217

melphalan: aplastic anemia, 4t; GOG 7601, 3, 20; GOG 7602, 6; secondary cancers, 5, 9

mesenchymal subtype of ovarian cancer, 151

metabolic toxicity. See toxicity, metabolic

methoxypolyethylene glycol, 127

metoclopramide, 11

MITO. See Multicentre Italian Trials in Ovarian Cancer


MITO-7 (Pignata 2014), 46, 126, 157–161

MITO16MANGO2b trial, 151

mixed effects model, 241

MRC. See Medical Research Council mucinous histology: no benefit with dose-dense paclitaxel administration, 123; poor response to chemotherapy, 199

—1

—0

—+1
mucositis. See toxicity, mucositis

Multicentre Italian Trials in Ovarian Cancer (MITO), 126, 157, 243

multidrug resistance, 215

multigated angiography, 245

multiple comparisons, GOG 218, 154

multiple gated acquisition scan, 211

myalgia. See toxicity, myalgia

myelodysplastic syndrome, 42

myelotoxicity. See toxicity, myelotoxicity

nail changes. See toxicity, nail changes

National Cancer Institute (NCI), 115

National Cancer Institute of Canada Clinical Trials Group (NCI-C-CTG), 80, 138, 145, 174, 222, 243

nausea. See toxicity, nausea

NCCTG. See North Central Cancer Treatment Group

NCI. See National Cancer Institute

NCI-C-CTG. See National Cancer Institute of Canada Clinical Trials Group

negative second look in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, negative second look

neoadjuvant chemotherapy: CHORUS, 178–185; EORTC 55971, 174–178; fibrosis, 178; meta-analysis, 174, 179; worse outcome, 174

neuropathy. See toxicity, neurotoxicity

neurotoxicity. See toxicity, neurotoxicity

neutropenia. See toxicity, neutropenia

New York State Heart Association Classification System, Doxil Study 30–49, 209

NOCOVA. See Nordic Gynecological Cancer Study Group

nonassessable disease, topotecan versus paclitaxel trial, 204

non-inferiority study: AGO-OVAR-3, 103; CALYPSO, 246; CHORUS, 182; GOG 158, 96, 99

non-measurable ovarian cancer: GOG 97, 54; no benefit to adding cisplatin, 49; topotecan versus paclitaxel trial, 204

Nonprofit Italian Association for Cancer Research, 126

non-proportional hazards, ICON7, 148

Nordic Gynecological Cancer Study Group (NOCOVA), 80

Nordic Society for Gynecologic Oncology (NSGO), 90, 132, 145, 243

North Central Cancer Treatment Group (NCCTG), 15

Nscore neurotoxicity assessment, SCOTROC, 109

NSGO. See Nordic Society for Gynecologic Oncology

nuclear magnetic resonance (NMR), MITO-7, 159

number of treatment cycles: AGO-OVAR-3, 102; AGO-OVAR9, 134; AGO-OVAR/NCIC/EORTC trial, 224; CALYPSO, 244; Danish Netherlands Trial, 76–77, 79; Doxil Study 30–49, 210; EORTC-GCG 55865, 164; gemcitabine versus PLD trial, 230; GOG 157, 40; GOG 218, 156; JGOG 3016, 124; non-serous histology, 44–45; OCEANS, 251; OV-10, 82, 85; optimal duration unknown, 38; OV16, 139; OVA-301, 237; pegylated liposomal doxorubicin, 210; SCOTROC, 107; serous histology, 44–45; topotecan, 210; topotecan versus paclitaxel trial, 203

observation in early-stage ovarian cancer: trials advocating, 5, 24, 25, 29, 30–31, 32, 37, 42–43; trials including, 3, 11, 21, 23–24, 25, 26, 33, 36

occult stage III ovarian cancer: impact of chemotherapy in non-optimally-staged patients, 30; rate in early-stage ovarian cancer, 25

OCEANS (Aghajanian 2012), 156, 200, 249–256, 262

optimal cytoreduction: definition, 50; GOG 52, 50; GOG 104, 62; GOG 111, 86; GOG 158, 96; GOG 172, 110; GOG 178/SWOG 9701, 187; GOG 182/ICON5, 115; GOG 218, 152; JGOG 3016, 124; OV-10, 80; rate in CHORUS, 183; rate in EORTC 55971, 178; survival benefit, 163

ototoxicity. See toxicity, ototoxicity

OV-10 (Piccart 2000), 46, 74, 80–86, 90, 91, 95, 100, 105, 191, 201

OV16 (Hoskins 2010), 46, 120, 137–144

OVA-301 (Monk 2010), 200, 235–242

Ovarian Cancer Study Group, 1, 5

overall response rate, OVA-301, 239, 241

overall survival, 225
overall survival as primary endpoint: ACTION, 27; AGO-OVAR9, 134; CHORUS, 182; EORTC 55971, 175; GOG 218, 153; ICONI, 34; ICONI/ACTION, 21; ICON4/AGO-OVAR 2.2, 219

overall survival in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, overall survival.

overall survival in high-risk early-stage ovarian cancer. See early-stage ovarian cancer, high-risk, overall survival.

overall survival in low-risk early-stage ovarian cancer. See early-stage ovarian cancer, low-risk, overall survival.

overall survival in recurrent ovarian cancer. See recurrent ovarian cancer, overall survival.

overall survival in stage I ovarian cancer. See stage I ovarian cancer, overall survival.

paclitaxel: 3 vs. 24-hour infusion, 75, 80, 99, 201, 206–207; activity in platinum-resistant ovarian cancer, 256; antiangiogenic effect, 157, 191, 193, 194; AURELIA, 258; cardiac effects, 60; combination-treatment efficacy, 60, 86; combined with bevacizumab, 258; data supporting extended use, 187, 191; discontinuation, 82; dose-dense administration, 120, 161; dose escalation, 81; dose modifications, 59, 71, 169, 188; FDA approval, 235; GOG 132, 70–71; GOG 178/SWOG 9701, 186–193; higher dose in GOG 132, 71; hypersensitivity reaction, 106, 152; ICON4/AGO-OVAR 2.2, 219; impact of duration versus dose, 192; inferiority to platinum, 72; maintenance therapy, 186–193, 193–199, 194, 195; maximum dose, 196; maximum tolerated dose, 101; methoxypolyethylene glycol, 127; myeloprotective effect, 220; not mandatory in upfront treatment, 90–95, 185; premedication regimen, 39, 59, 76, 81, 88, 96, 106, 169, 196; prolonged circulation, 127; recurrent ovarian cancer, 243; response rates, 201, 206–207, 217; single-agent efficacy, 58, 201; therapeutic ratio, 192; timing of administration, 95; topotecan versus paclitaxel study, 200–207, 234, 242; toxicity, 197; weekly administration, 157, 158, 195

paclitaxel + carboplatin (TC): AGO-OVAR-3, 99, 101; AGO-OVAR9, 133; CALYPSO, 244; Danish Netherlands Trial, 79, 99; EORTC 55971, 175; equivalence to paclitaxel + cisplatin (TP), 99; GOG 157, 39; GOG 158, 96, 99; GOG 175, 193–199; GOG 182/ICON5, 116; GOG 218, 152; ICON3, 91, 92, 100; ICON7, 146; JGOG 3016, 120; less toxicity than paclitaxel + cisplatin, 79; maximum tolerated dose, 101–102; MITO-7, 157–161, myelosuppression, 105; number of cycles, 38, 40; OV16, 139; quality of life, 103; platinum-sensitive recurrent ovarian cancer, 217–221, 243, 246; residual neurotoxicity rate, 132; response rate, 96, 105; SCOTROC, 106; standard therapy for advanced ovarian cancer, 38, 100, 119, 187, 194; toxicities, 157, 161; weekly administration, 157–161; with third chemotherapy drug, 114–119, 120, 132–137, 137–144

paclitaxel + cisplatin (TP): 24-hour paclitaxel infusion, 58; 3-hour paclitaxel infusion, 76, 80; AGO-OVAR-3, 99, 101; better toxicity profile than high-dose monotherapy, 72; CHORUS, 180; Danish Netherlands Trial, 79, 99; dose adjustment, 71, 82; equivalence to non-taxane platinum regimen, 95; GOG 111, 59–60, 80, 100; GOG 114, 87; GOG 132, 70, 71; GOG 152, 168–173; GOG 158, 96, 99; GOG 172, 110; MITO-2, 128; neurotoxicity, 91; OV-10, 80, 81, 100; overall survival, 105; quality of life, 103; response rates, 105; sequential therapy, 74; standard of care, 75, 86, 91, 201; superiority over cyclophosphamide + cisplatin (CP) regimen, 60, 74, 83, 90; toxicity, 95

pain. See toxicity, pain

paired T-test, AGO-OVAR/NCIC/EORTC trial, 227

palliation, goal of therapy for recurrent ovarian cancer, 233

palmar-plantar erythrodysesthesia (PPE). See toxicity, palmar-plantar erythrodysesthesia
paracentesis, AURELIA, 261
partial response (PR): Doxil Study 30–49, 211; GOG 47, 48; topotecan versus paclitaxel trial, 203
pathologic response in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, pathologic complete response
pathologic response rate: GOG 97, 55, 57; GOG 104, 63, 64; with intraperitoneal cisplatin, 64
patient-reported outcomes, 262
Pearson’s Chi-square test: GOG 104, 64; GOG 111, 60; GOG 114, 88
pegylated liposomal doxorubicin (PLD): approved agent, 208, 235; area under the curve, 208; AURELIA, 258; cardiac monitoring, 211, 214; clearance, 116, 208; combined with bevacizumab, 258; combined with carboplatin, 127, 243–244; combined with paclitaxel and carboplatin, 116; cumulative dose, 211, 214, 230, 238, 245; dose modifications, 208, 210; dosing every 3 weeks, 127, 237; dosing every 4 weeks, 116, 210, 230, 237, 244; Doxil study, 207–217, 242; elimination half-life, 208; equivalent to topotecan, 200–207, 229, 234; FDA approval, 235; gemcitabine versus PLD trial, 228–234; pegylated liposomes, 127, 208; platinum-resistant ovarian cancer, 22, 256; platinum-sensitive ovarian cancer, 215, 217; prevention of multidrug resistance, 215; recurrent ovarian cancer, 115, 127, 132, 243; response rates, 208; safety profile, 216, 217; synergy with trabectedin, 236; therapeutic benefit, 208; toxicities, 208, 210, 215, 234; volume of distribution, 208
pegylated liposomal doxorubicin + carboplatin. See carboplatin + pegylated liposomal doxorubicin (PLD)
pelvic ultrasonography, 3, 6, 11
performance status: ECOG, 101, 106, 120, 127, 133, 139, 146, 158, 202, 223, 236, 244, 250, 257; GOG, 54, 58, 71, 87, 96, 110, 115, 152, 169, 195; Karnofsky, 209; prognostic factor, 233; World Health Organization (WHO), 76, 81, 174; Zubrod, 230
peripheral edema. See toxicity, peripheral edema
PharmaMar, 235
platelet count, prognostic impact, 79
platelet toxicity. See toxicity, platelet
platinum, efficacy in ovarian cancer: ACTION, 23; GICOG trials, 15; GOG 95, 9; ICON1, 23, 35; meta-analysis, 36, 66
platinum-free interval, impact on probability of response to treatment, 217
platinum-resistant ovarian cancer: AURELIA, 257, 260; bevacizumab activity, 250, 260; definition, 217, 256; choice of chemotherapy agents, 217, 229, 242, 256; gemcitabine, 228–234; gemcitabine versus PLD trial, 229; OVA-301, 236; overall survival, 256; paclitaxel activity, 58, 70; pegylated liposomal doxorubicin activity, 228–234, 242; progression-free survival, 260; topotecan activity, 138; topotecan versus paclitaxel trial, 204
platinum-sensitive ovarian cancer: AGO-OVAR/NCIC/EORTC trial, 223, 249; CALYPSO, 24, 2464; choice of chemotherapy agents, 217, 222, 242, 249, 255–256; definition, 217; gemcitabine activity, 133; ICON4/AGO-OVAR 2.2, 218; OCEANS, 253; OVA-301, 236; overall survival, 127; paclitaxel activity, 70; paclitaxel plus platinum activity, 220; pegylated liposomal doxorubicin (PLD) activity, 127, 214, 242; pegylated liposomal doxorubicin (PLD) + carboplatin activity, 127, 246; progression-free survival, 127, 249; response rate, 127; topotecan activity, 127
PLD. See pegylated liposomal doxorubicin posterior reversible encephalopathy syndrome (PRES). See toxicity, posterior reversible encephalopathy syndrome postoperative mortality, CHORUS, 185
power analysis. See sample size
primary cytoreduction: CHORUS, 180; EORTC 55971, 175; standard of care, 174, 179
proctosigmoidoscopy, 3, 6, 11
progression: AGO-OVAR/NCIC/EORTC trial, 225; GOG 152, 171; GOG 178/ SWOG 9701, 191; greater hazard for
progression after maintenance paclitaxel, 191; OCEANS, 252

progression-free interval in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, progression-free interval

progression-free survival, 225

progression-free survival as primary endpoint: AGO-OVAR/NCIC/EORTC trial, 225; AURELIA, 259; CALYPSO, 246; Danish Netherlands Trial, 77; determined by investigators, 252, 259; endorsed by AACR ASCO and FDA, 235, 239; endorsed by GCIG, 157; gemcitabine versus PLD trial, 231; GOG 52, 52; GOG 111, 60; GOG 132, 72; GOG 178/SWOG 9701, 189, 192; GOG 218, 153; ICON7, 147; JGOG 3016, 122; median, 144; MITO-2, 129; MITO-7, 159; OCEANS, 252; OV-10, 83; OV16, 141; OVA-301, 238; rationale, 192, 228, 248; SCOTROC, 109

progression-free survival in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, progression-free survival

progression-free survival in recurrent ovarian cancer. See recurrent ovarian cancer, progression-free survival

progressive disease: Doxil Study 30–49, 211; MITO-2, 129; OV16, 141; topotecan versus paclitaxel, 204

proportional hazards model: CHORUS, 183; Grambsch-Therneau test, 183; GOG 95, 17; GOG 97, 55; GOG 111, 60; GOG 152, 171; GOG 157, 40

proportion without progression as primary endpoint, AGO-OVAR-3, 103

proteinuria. See toxicity, proteinuria

pulmonary toxicity. See toxicity, pulmonary

QLQ-C30 questionnaire: AGO-OVAR-3, 102; AGO-OVAR9, 134; AGO-OVAR/NCIC/EORTC trial, 224, 227; CALYPSO, 245; CHORUS, 181; domains, 140, 211; Doxil Study 30–49, 211; EORTC 55971, 175; ICON7, 147; OV16, 140; OVA-301, 238; SCOTROC, 107; symptom scales, 211

QLQ-OV28 questionnaire: AGO-OVAR9, 134; AGO-OVAR/NCIC/EORTC trial, 224, 227; CALYPSO, 245; CHORUS, 181; EORTC 55971, 175; ICON7, 147; OV16, 140; OVA-301, 238; questions related to ovarian cancer symptoms and treatments, 141; SCOTROC, 107

quality of life: AGO-OVAR9, 134; AGO-OVAR/NCIC/EORTC trial, 224, 227; CALYPSO, 245; CHORUS, 181, 183; Doxil Study 30–49, 211; endpoint, 83, 100, 102; EORTC 55971, 175; Functional Assessment of Cancer Therapy—Ovarian (FACT-O) questionnaire, 111, 153, 159, 231; gemcitabine versus PLD trial, 231, 233; goal in recurrent ovarian cancer, 215, 242; GOG 172, 111, 114; GOG 218, 153, 157; ICON4/AGO-OVAR 2.2, 219, 222; ICON7, 147; MITO-2, 129; MITO-7, 159; OV16, 140; OVA-301, 238, 241; prognostic factor, 233; QLQ-C30 questionnaire, 102, 107, 129, 134, 140–141, 147, 175, 181, 211, 224, 238, 245; QLQ-OV28 questionnaire, 107, 134, 140, 147, 175, 181, 224, 238, 245, 248; SCOTROC, 107; treatment toxicities, 126

radiotherapy: treatment option for early-stage ovarian cancer, 10; treatment option for recurrent ovarian cancer, 215

ranitidine, 81, 88, 106

RECIST (Response Evaluation Criteria in Solid Tumors): AGO-OVAR9, 134; AURELIA, 257; CALYPSO, 244, 245; gemcitabine versus PLD trial, 230; GOG 218, 153; ICON7, 147; MITO-2, 129; MITO-7, 159; OV16, 140; OVA-301, 238, 241; SCOTROC, 107

RECIST response in advanced-stage ovarian cancer. See advanced-stage ovarian cancer, RECIST response

RECIST response in recurrent ovarian cancer. See recurrent ovarian cancer, RECIST response

RECIST response in recurrent ovarian cancer. See recurrent ovarian cancer, RECIST response

reurrence definition, GOG 178/SWOG 9701, 189

recurrence-free survival: definition, 29, 34; suboptimal staging, 43

recurrence-free survival in high-risk early-stage ovarian cancer. See early-stage ovarian cancer, high-risk, recurrence-free survival
recurrence patterns: ACTION, 28t; GICOG trials, 13t, 14t; GOG 7602, 9
recurrence rate as primary endpoint: GOG 157, 40; GOG 175, 196
recurrence rate in high-risk early-stage ovarian cancer. See early-stage ovarian cancer, high-risk, recurrence rate
recurrent ovarian cancer, disease-control rate: gemcitabine, 231t; gemcitabine versus PLD trial, 231, 231t; pegylated liposomal doxorubicin, 231t
recurrent ovarian cancer, duration of response: AGO-OVAR/NCIC/EORTC trial, 225, 226t; carboplatin, 226t; carboplatin + gemcitabine, 226t, 254t; carboplatin + gemcitabine + bevacizumab, 254t; OCEANS, 254t; OVA-301, 239; paclitaxel, 205t; topotecan, 205t; topotecan versus paclitaxel trial, 205–206t
recurrent ovarian cancer, overall survival: AGO-OVAR/NCIC/EORTC trial, 226t; AURELIA, 261t; carboplatin, 226t; carboplatin + gemcitabine, 226t, 254t; carboplatin + gemcitabine + bevacizumab, 254t; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t; Doxil study 30–49, 213t; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; ICON4/AGO-OVAR 2.2, 221t; OCEANS, 254t; OVA-301, 240t; paclitaxel, 205–206t; paclitaxel + carboplatin (TC), 247t; pegylated liposomal doxorubicin, 213t, 240t; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; platinum-resistant, 213t, 240t; platinum-sensitive, 213t, 240t; topotecan, 205–206t; topotecan versus paclitaxel trial, 205–206t
recurrent ovarian cancer, progression by CA125: AURELIA, 261t; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t
recurrent ovarian cancer, response rate: AGO-OVAR/NCIC/EORTC trial, 226t; AURELIA, 261t; carboplatin, 226t; carboplatin + gemcitabine, 226t, 254t; carboplatin + gemcitabine + bevacizumab, 254t; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; ICON4/AGO-OVAR 2.2, 221t; OCEANS, 254t; pegylated liposomal doxorubicin, 213t, 240t; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; platinum-resistant, 213t, 240t; platinum-sensitive, 213t; topotecan, 205t, 213t; topotecan versus paclitaxel trial, 205–206t
recurrent ovarian cancer, progression by CA125: CALYPSO, 247t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 247t; paclitaxel + carboplatin (TC), 247t
recurrent ovarian cancer, progression-free survival: AGO-OVAR/NCIC/EORTC trial, 226t; AURELIA, 261t; CALYPSO, 247t; carboplatin, 226t; carboplatin + gemcitabine, 226t, 254t; carboplatin + gemcitabine + bevacizumab, 254t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 247t; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t; Doxil study 30–49, 213t; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; ICON4/AGO-OVAR 2.2, 221t; OCEANS, 254t; pegylated liposomal doxorubicin + trabectedin, 240t; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; platinum-resistant, 213t, 240t; platinum-sensitive, 213t, 240t; topotecan, 205–206t; topotecan versus paclitaxel trial, 205–206t
Index

recurrent ovarian cancer, time to response:
  paclitaxel, 205–206t; topotecan, 205–206t;
  topotecan versus paclitaxel trial, 205–206t
relapse: early relapse, 204; interim relapse,
  204; late relapse, 204; resistant disease, 204
relapse-free survival, 12
renal function: AGO-OVAR-3, 101;
  AGO-OVAR9, 133; AGO-OVAR/NCIC/EORTC
  trial, 223; Danish Netherlands Trial, 75–76;
  Doxil Study 30–49, 209;
  GOG 97, 54; GOG 104, 62; GOG 111, 58;
  GOG 114, 87; GOG 132, 71; GOG 152,
  169; GOG 158, 96; GOG 182/ICONS,
  115; JGOG 3016, 120; OV16, 138;
  OVA-301, 236; topotecan versus
  paclitaxel study, 202
renal toxicity. See toxicity, renal
residual disease status, prognostic impact,
  52, 64, 79, 113, 178, 179, 183
response duration, GOG 97, 57
response duration in advanced-stage
  ovarian cancer. See advanced-stage
  ovarian cancer, response duration
Response Evaluation Criteria in Solid
  Tumors (RECIST). See RECIST
response rate: Cochran-Mantel Haenszel
test, 253; lack of correlation with
  survival, 137; phase II endpoint, 137
response rate as primary endpoint, GOG
  47, 48
response rate in advanced-stage ovarian
  cancer. See advanced-stage ovarian
  cancer, response rate
response rate in recurrent ovarian cancer.
  See recurrent ovarian cancer, response rate
restricted maximum likelihood, GOG 172,
  112
restricted mean difference, ICON7, 148
reversible posterior leukoencephalopathy
  syndrome. See toxicity, reversible
  posterior leukoencephalopathy syndrome
  (RPLS)
RPLS. See toxicity, reversible posterior
  leukoencephalopathy syndrome
SAAK. See Swiss Group for Clinical
  Cancer Research
salvage therapy: better treatments needed,
  52; early-stage ovarian cancer, 25, 30;
intraperitoneal, 62; paclitaxel activity,
  58; timing of initiation, 74
sample size: ACTION, 27; AGO-OVAR-3,
  103; AGO-OVAR9, 135; AGO-OVAR/
  NCIC/EORTC trial, 225; AURELIA,
  260; CHORUS, 182; Danish Netherlands
  Trial, 77; Doxil Study 30–49, 211;
  EORTC 55971, 176; EORTC-GCG 55865,
  165; Freedman's method, 231; gem-
  citabine versus PLD trial, 231; GOG 47,
  48; GOG 52, 52; GOG 95, 17; GOG 104,
  64; GOG 132, 72; GOG 152, 171; GOG
  157, 40; GOG 158, 97; GOG 172, 112;
  GOG 175, 196; GOG 178/SWOG 9701,
  189; GOG 182/ICONS, 117; GOG 218,
  154; GOG 7601, 3; GOG 7602, 7; ICON1,
  34; ICON2, 68; ICON3, 92; ICON4/
  AGO-OVAR 2.2, 220; ICON7, 147;
  JGOG 3016, 123; MITO-2, 129; MITO-7,
  159; OCEANS, 252; OV-10, 83; OV16,
  141; OVA-301, 239; SCOTROC, 109
Schering-Plough Italy, 126
Schoenfeld residuals, OV16, 142
SCOTROC (Vasey 2004), 46, 105–109
Scottish Group, 80
Scottish Gynacological Cancer Trials
  Group, 105
secondary debulking surgery: difficulty in
  assessing efficacy, 173; EORTC-GCG
  55865, 162–168; GOG 152, 168–173;
  JGOG 3016, 122; timing after chemo-
  therapy, 170
secondary malignancy. See toxicity,
  secondary malignancy
second-line chemotherapy: impact on
  overall survival, 192; non-curative, 191
second-look surgery: AGO-OVAR-3, 103;
  does not influence survival, 52; EORTC
  55971, 175; EORTC-GCG 55865, 164;
  GOG 47, 47; GOG 52, 51; GOG 97, 55;
  GOG 104, 63, 64; GOG 111, 60; GOG
  114, 88, 90; GOG 158, 97; GOG 172, 111;
  JGOG 3016, 122; no clinical benefit, 117;
  OV-10, 82
sepsis. See toxicity, sepsis
serous histology: number of chemotherapy
  cycles, 44–45; response to chemotherapy,
  44–45
SIAK. See Swiss Institute for Cancer
  Research
skin toxicity. See toxicity, skin
small bowel perforation. See gastrointestinal perforation
SmithKline Beecham Pharmaceuticals, 200
Southwest Oncology Group (SWOG), 15, 86, 115, 187
splenectomy, CHORUS, 181
stable disease: Doxil Study 30–49, 211; topotecan versus paclitaxel trial, 204
stage, prognostic impact, 79, 131, 178
stage I ovarian cancer, disease-free survival: cisplatin, 13t; GICOG trials, 13t; GOG 7601, 4t; melphalan, 4t; no further treatment, 4t, 13t
stage I ovarian cancer, overall survival: GOG 7601, 4t; melphalan, 4t; no further treatment, 4t
stem cell support, treatment option for recurrent ovarian cancer, 215
stomatitis. See toxicity, stomatitis
stratification factors: age, 141, 189, 204; ascites, 204; bulky disease, 212; cell type, 3, 7; center, 129, 141, 182, 219, 246; chemotherapy regimen, 182, 260; clinical response, 165; differentiation, 34; first-line therapy, 225; GCIG group, 147; grade, 27; histologic grade, 3, 7; institution, 27, 34, 165, 176; intended platinum treatment, 219; interval between surgery and chemotherapy, 147; largest preoperative tumor size, 176; last chemotherapy received, 219; measurable disease, 171, 225, 246; method of biopsy, 176; minimization technique, 165; optimal versus suboptimal, 189; performance status, 129, 154, 165, 237; platinum-free interval, 225, 252, 260; platinum sensitivity, 212, 237; prior antiangiogenic therapy, 260; prior treatment with paclitaxel, 189; radiologic tumor size, 182; residual disease, 112, 129, 141, 154; residual tumor size, 103, 135, 147; response to chemotherapy, 171, 204; secondary debulking surgery, 220; second-look surgery, 112; stage, 7, 27, 34, 103, 129, 135, 147, 154, 176, 182; surgery for recurrence, 252; therapy-free interval, 246; time since completion of last chemotherapy, 219, 220
subgroup analysis, 21
suboptimal debulking: EORTC-GCG 55865, 164, 168; GOG 47, 47; GOG 97, 54; GOG 111, 58; GOG 132, 71; GOG 152, 168–169; GOG 178/SWOG 9701, 187; GOG 182/ICON5, 115; GOG 218, 152; ICON7, 146; JGOG 3016, 124; OV-10, 80; overall survival, 43
surgical morbidities, CHORUS, 185
surgical re-exploration: GOG 7601, 3; GOG 7602, 7
surgical staging: description, 2, 6, 11, 16, 20, 26, 39, 195; improved survival, 30; incomplete documentation, 42; prognostic factor, 2, 30; trials including comprehensive staging, 2, 16, 20, 39, 195; trials lacking comprehensive staging, 24, 26, 33
survival as endpoint: ACTION, 21, 27; GOG 104, 63; GOG 7601, 3; GOG 7602, 7; GICOG trials, 12; ICON1, 21, 34; ICON2, 68
survival in advanced-stage ovarian cancer: bulky disease with complete response to chemotherapy, 173; gross optimal, 119; microscopic residual, 119; not otherwise specified, 100, 115; optimal, 176; platinum-sensitive, 216, 220; suboptimal, 119; suboptimal primary debulking and interval debulking, 176
survival in early-stage ovarian cancer, 2, 10, 15, 19, 20, 36, 193, 197
survival in high-risk early-stage ovarian cancer: GOG 7602, 9, 38; GOG 95, 17, 19; ICON1, 36
survival in low-risk early-stage ovarian cancer: GOG 7601, 5, 15, 37; stage I, 197; stage Ia, (GOG 7601), 5; stage Ib, ovarian cancer (GOG 7601), 5; stage II, 197
survival in stage III ovarian cancer: GOG 158, 99; GOG 172, 114
Swiss Group for Clinical Cancer Research (SAAK), 32, 90
Swiss Institute for Cancer Research (SIAK), 66
SWOG. See Southwest Oncology Group
Taxol. See paclitaxel
TC. See paclitaxel + carboplatin
Tenckhoff catheter, 88
therapeutic ratio, 192
therapy-free interval, prognostic factor, 248
thrombocytopenia. See toxicity, platelet
thromboembolism. See toxicity, thromboembolism
time to failure in recurrent ovarian cancer. 
See recurrent ovarian cancer, time to failure
time to progression as primary endpoint, 
Doxil Study 30–49, 212
time to progression in recurrent ovarian cancer. 
See recurrent ovarian cancer, time to progression
time to response in recurrent ovarian cancer. 
See recurrent ovarian cancer, time to response
timing of chemotherapy initiation, no 
prognostic impact, 52
tinnitus. See toxicity, tinnitus
topoisomerase inhibitor, topotecan, 201
topotecan (Hycamtin): 3-day dosing, 142;
5-day dosing, 144, 202–203, 210, 258;
approved agent, 208, 235; AURELIA,
258; camptothecin analogue, 138, 201;
combined with bevacizumab, 258;
combined with paclitaxel and carbopla-
itin, 116, 137, 137–144; dose escalation,
203; dose-limiting toxicity, 202, 207;
dose reduction, 203; Doxil study,
207–217, 242; equivalent to pegylated 
liposomal doxorubicin, 200–207, 234;
FDA approval, 235; GOG182/ICON5,
142; intermittent daily dosing, 202; lack of 
cross-resistance to platinum and 
taxanes, 208; maximum tolerated dose,
202; platinum-resistant ovarian cancer, 
229, 256; recurrent ovarian cancer, 115;
refractory ovarian cancer, 144; response 
rates, 208; sequential doublet, 138, 139;
topoisomerase inhibitor, 201; topotecan 
versus paclitaxel study, 200–207, 234,
242; treatment discontinuation, 203;
toxicities, 210, 215; weekly dosing, 258
Topotecan versus paclitaxel (ten Bokkel 
1997), 115, 200, 200–207, 229, 234, 242,
243
toxicity, abdominal pain: cyclophospha-
mide + cisplatin (CP), 65t; GOG 104, 66,
65t; GOG 172, 111; GOG 7602, 8t;
intraperitoneal 132P, 8t; intraperitoneal 
cisplatin-based chemotherapy, 65t; 

paclitaxel + carboplatin (TC), 108t; 
SCOTROC, 108t

toxicity, allergic reaction: CALYPSO,
248t; carboplatin + pegylated liposomal 
doxorubicin (C-PLD), 248t;
cyclophosphamide + cisplatin (CP),
61t; Danish Netherlands Trial, 79;
docetaxel + carboplatin, 108t; GOG 111,
59, 61t; OV16, 145t; paclitaxel +
carboplatin (TC), 145t, 248t; paclitaxel +
cisplatin (TP), 61t; SCOTROC, 108t
toxicity, alopecia: AGO-OVAR/NCIC/ 
EORTC trial, 227t, 228; CALYPSO,
246, 248t; carboplatin, 69t, 94t, 227t;
carboplatin + gemcitabine, 227t, 228;
carboplatin + pegylated liposomal 
doxorubicin (C-PLD), 130t, 248t;
cyclophosphamide + cisplatin (CP), 61t,
85t; cyclophosphamide + doxorubi-
cin + cisplatin (CAP), 69t, 94t; Danish 
Netherlands Trial, 79; Doxil study
30–49, 214t; GOG 111, 61t; GOG 132, 72;
GOG 178/SWOG 9701, 193; ICON2, 69t,
70, ICON3, 94t, 95; ICON4/AGO-OVAR
2.2, 221t; MITO-2, 130t, 131, 161;
MITO-7, 160t, 161; OV-10, 85t; pacli-
taxel, 206t; paclitaxel + carboplatin (TC),
94t, 95, 108t, 130t, 160t, 161, 243,
248t; paclitaxel + cisplatin (TP), 61t, 85t;
pegylated liposomal doxorubicin (PLD),
127, 214t; platinum chemotherapy, 221t;
platinum + paclitaxel, 221t; SCOTROC,
108t; topotecan, 206t, 214t; topotecan
versus paclitaxel trial, 206t; weekly 
paclitaxel + carboplatin, 160t


toxicity, anaphylaxis, OV16, 140

toxicity, anemia: AGO-OVAR/NCIC/ 
EORTC trial, 226t; AGO-OVAR-3, 104t;
AGO-OVAR9, 136t; carboplatin, 226t;
carboplatin + gemcitabine, 226t;
carboplatin + pegylated liposomal 
doxorubicin (C-PLD), 130t; cisplatin, 73t;
cyclophosphamide + cisplatin (CP), 56t,
61t, 65t; Danish Netherlands Trial, 78t;
docetaxel + carboplatin, 108t; dose-dense 
paclitaxel + carboplatin, 125t; Doxil 
study 30–49, 214t; gemcitabine, 233t;
gemcitabine versus PLD trial, 233t;
GOG 97, 56t; GOG 104, 65t; GOG 111,
61t; GOG 132, 73t, 74; GOG 157, 41t;

---1
---0
---+1
toxicity, anemia (cont.)
GOG 182/ICON5, 118t; intraperitoneal cisplatin-based chemotherapy, 65t; JGOG 3016, 125t, 161; MITO-2, 130t; MITO-7, 161; OCEANS, 252; paclitaxel, 73t, 206t; paclitaxel + carboplatin (TC), 41t, 104t, 108t, 118t, 136t, 161; paclitaxel + carboplatin (TC), 78t, 104t, 125t, 130t; paclitaxel + cisplatin (TP), 61t, 73t, 78t; pegylated liposomal doxorubicin (PLD), 214t, 233t; SCOTROC, 108t; topotecan, 206t, 214t; topotecan versus paclitaxel trial, 206t
toxicity, anorexia, MITO-2, 131

toxicity, arterial thrombosis: AURELIA, 261t; bevacizumab, 153; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t; GOG 218, 153, 156t; paclitaxel + carboplatin (PC), 156t; paclitaxel + carboplatin + bevacizumab (PCB), 156t
toxicity, arthralgia: CALYPSO, 248t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 248t; cyclophosphamide + cisplatin (CP), 85t; Danish Netherlands Trial, 79; OV-10, 85t; OV16, 140; paclitaxel, 206t; paclitaxel + carboplatin (TC), 108t, 248t; paclitaxel + cisplatin (TP), 85t; SCOTROC, 108t; topotecan, 206t; topotecan versus paclitaxel trial, 206t
toxicity, bilirubin, Doxil Study 30–49, 210
toxicity, bleeding: carboplatin + pegylated liposomal doxorubicin (C-PLD), 131t; GOG 218, 156t; ICON7, 150t; MITO-2, 131t; paclitaxel + carboplatin (TC), 131t, 150t, 156t; paclitaxel + carboplatin + bevacizumab (PCB), 150t, 156t
toxicity, cardiac: Danish Netherlands Trial, 79; doxorubicin, 208; GOG 111, 59–60; GOG 114, 89t; GOG 172, 113t; GOG 175, 197, 198t; intraperitoneal cisplatin-based chemotherapy, 89t, 113t; maintenance chemotherapy, 198t; maintenance paclitaxel, 197; OV-10, 82; paclitaxel + cisplatin (TP), 89t, 113t; pegylated liposomal doxorubicin (PLD), 127
toxicity, cardiac ischemia, GOG 111, 60
toxicity, central nervous system bleeding: GOG 218, 156t; paclitaxel + carboplatin (TC), 156t; paclitaxel + carboplatin + bevacizumab (PCB), 156t
toxicity, congestive heart failure: OVA-301, 240t; pegylated liposomal doxorubicin (PLD), 240t; pegylated liposomal doxorubicin + trabectedin, 240t
toxicity, constipation: Danish Netherlands Trial, 79; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; pegylated liposomal doxorubicin, 231t
toxicity, cutaneous. See toxicity, skin
toxicity, death due to treatment: CALYPSO, 248t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t, 248t; cyclophosphamide + cisplatin (CP), 61t, 65t; docetaxel + carboplatin, 108t; GOG 104, 65t; GOG 111, 61t; Doxil study 30–49, 214t; GOG 114, 89t; GOG 172, 113t; GOG 218, 155t; ICON7, 150t; intraperitoneal cisplatin-based chemotherapy, 65t, 89t, 113t; MITO-2, 130t; MITO-7, 160t; OV16, 143t; OVA-301, 241t; paclitaxel + carboplatin (TC), 108t, 130t, 143t, 150t, 155t, 160t, 248t; paclitaxel + carboplatin + bevacizumab (PCB), 150t, 155t; paclitaxel + cisplatin (TP), 61t, 89t, 113t; pegylated liposomal doxorubicin (PLD), 214t, 241t; pegylated liposomal doxorubicin + trabectedin, 241t; SCOTROC, 108t; topotecan, 214t, 215; weekly paclitaxel + carboplatin, 160t
toxicity, dermatologic. See toxicity, skin
toxicity, diarrhea: carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t; Danish Netherlands Trial, 79; MITO-2, 130t, 131t; paclitaxel + carboplatin (TC), 130t; paclitaxel + cisplatin (TP), 169; topotecan versus paclitaxel trial, 207
toxicity, dyspnea: gemcitabine, 233t; gemcitabine versus PLD trial, 233t; GOG 104, 66; pegylated liposomal doxorubicin (PLD), 233t
toxicity, fatigue: AGO-OVAR9, 137; GOG 172, 112, 113t; gemcitabine, 231t, 233t; gemcitabine versus PLD trial, 231t, 233t; intraperitoneal cisplatin-based chemotherapy, 113t; paclitaxel + carboplatin (TC), 157; paclitaxel + cisplatin (TP), 113t; pegylated liposomal doxorubicin (PLD), 231t, 233t
Index

---1
---0
---+1
toxicity, hemorrhagic cystitis, GOG 97, 55
toxicity, hepatic: GOG 172, 113t; GOG 182/ ICONS, 118t; intraperitoneal cisplatin-
based chemotherapy, 113t; Hy’s law, 241;
OVA-301, 238, 240t, 241; paclitaxel+
carboplatin (TC), 118t; paclitaxel+
cisplatin (TP), 113t; pegylated liposomal
doxorubicin (PLD), 240t; pegylated liposomal doxorubicin + trabectedin,
240t, 241; SCOTROC, 106
toxicity, hospitalization: OV16, 145t;
apaclitaxel + carboplatin (TC), 145t
toxicity, hypersensitivity: bevacizumab,
153; CALYPSO, 246, 248, 248t;
carboplatin + pegylated liposomal
doxorubicin (C-PLD), 248t;
cyclophosphamide + cisplatin (CP), 85t;
dose-dense paclitaxel + carboplatin, 125t;
GOG 218, 152, 153; JGOG 3016, 125t;
OV-10, 82, 85t; paclitaxel, 106, 152;
apaclitaxel + carboplatin (TC), 125t, 248t;
apaclitaxel + cisplatin (TP), 85t; SCOTROC,
106
toxicity, hypertension: AURELIA, 257,
261t, 262; bevacizumab, 153, 157;
carboplatin + gemcitabine, 254t;
carboplatin + gemcitabine + bevacizumab,
254t; chemotherapy alone, 261t;
chemotherapy + bevacizumab, 261t; GOG
218, 153, 155t, 156, 157; ICON7, 150t;
OCEANS, 254t; paclitaxel + carboplatin
( TC), 150t, 155t; paclitaxel + carboplatin +
bevacizumab (PCB), 150t, 155t
toxicity, infection: AGO/OVAR-3, 104t;
carboplatin + pegylated liposomal
doxorubicin (C-PLD), 131t; cyclophos-
phamide + cisplatin (CP), 56t; GOG 97,
56t; GOG 114, 89t; GOG 172, 113t; GOG
175, 197, 198t; ICON4/OVAR 2.2,
221t; intraperitoneal cisplatin-based
chemotherapy, 89t, 113t; maintenance
chemotherapy, 198t; maintenance
paclitaxel, 197; MITO-2, 131t; OV16,
139; OVA-301, 237; paclitaxel, 206t;
apaclitaxel + carboplatin (TC), 104t, 131t;
apaclitaxel + cisplatin (TP), 89t, 104t, 113t;
platinum chemotherapy, 221t; plat-
imum + paclitaxel, 221t; topotecan, 206t;
topotecan versus paclitaxel trial, 203,
206t
toxicity, leukopenia: AGO/OVAR-3, 104t;
AGO-OVAR9, 136t; carboplatin, 69t;
carboplatin + pegylated liposomal
doxorubicin (C-PLD), 131t; cyclophos-
phamide + cisplatin (CP), 85t, 52t, 56t,
65t; cyclophosphamide + doxorubicin +
cisplatin (CAP), 52t, 69t; Doxil study
30–49, 214t; GOG 95, 18t; GOG 97, 56t;
GOG 104, 65t; GOG 114, 89t; GOG 158,
98t; GOG 172, 113t; ICON2, 69t, 70;
intraperitoneal 123I, 18t; intraperitoneal
cisplatin-based chemotherapy, 65t, 89t,
113t; MITO-2, 131t; paclitaxel +
carboplatin (TC), 98t, 104t, 131t, 136t;
apaclitaxel + cisplatin (TP), 89t, 98t, 104t,
113t; pegylated liposomal doxorubicin
(PLD), 214t; topotecan, 214t
toxicity, metabolic: GOG 114, 89t; GOG
158, 98t, 99; GOG 172, 112, 113t;
intraperitoneal cisplatin-based chemo-
therapy, 89t, 113t; paclitaxel + carboplatin
( TC), 98t; paclitaxel + cisplatin (TP), 89t,
98t, 113t

toxicity, mucositis: CALYPSO, 248, 248t;
carboplatin + pegylated liposomal
doxorubicin (C-PLD), 248t; Danish
Netherlands Trial, 79; gemcitabine,
231t; gemcitabine versus PLD trial, 231t;
ICON4/OVAR 2.2, 221t; MITO-2,
131; OV16, 140; OVA-301, 240t;
apaclitaxel + carboplatin (TC), 248t;
apaclitaxel + cisplatin (TP), 169; pegylated
liposomal doxorubicin (PLD), 116,
127, 231t, 240t; pegylated liposomal
doxorubicin + trabectedin, 240t; platinum
chemotherapy, 221t; platinum + paclitaxel,
221t; SCOTROC, 107
toxicity, myalgia: CALYPSO, 248t;
carboplatin + pegylated liposomal
doxorubicin (C-PLD), 248t; cyclophos-
phamide + cisplatin (CP), 85t;
Danish Netherlands Trial, 79; gemcitabine,
231t; gemcitabine versus PLD trial, 231t;
ICON4/OVAR 2.2, 221t; MITO-2,
131; OV16, 140; OVA-301, 240t;
apaclitaxel + carboplatin (TC), 248t;
apaclitaxel + cisplatin (TP), 169; pegylated
liposomal doxorubicin (PLD), 116,
127, 231t, 240t; pegylated liposomal
doxorubicin + trabectedin, 240t; platinum
chemotherapy, 221t; platinum + paclitaxel,
221t; SCOTROC, 107
toxicity, myelotoxicity: AGO-OVAR-3, 105;
carboplatin, 75; cyclophosphamide +
doxorubicin (CA), 49t; cyclophospha-
mide + doxorubicin + cisplatin (CAP), 49t; GOG 47, 49t; GOG 7601, 4t; GOG 7602, 8t; ICON4/AGO-OVAR 2.2, 220; limits intravenous chemotherapy intensity, 111; melphalan, 4t, 8t; OV-10, 82; pegylated liposomal doxorubicin (PLD), 127; SCOTROC, 109; topotecan, 202; topotecan combination therapy, 138 toxicity, nail changes: docetaxel + carboplatin, 108t; SCOTROC, 108t toxicity, nausea: AGO-OVAR/NCIC/EORTC trial, 226t; AGO/OVAR-3, 104t; CALYPSO, 248, 248t; carboplatin, 69t, 94t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 248t; cisplatin, 13t, 14t; cyclophosphamide + cisplatin (CP), 52t, 85t; cyclophosphamide + doxorubicin + cisplatin (CAP), 52t, 69t, 94t; Danish Netherlands Trial, 78t; doxorubicin, 208; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; GICO trials, 13t, 14t; ICON2, 69t, 70; ICON3, 94t; ICON4/AGO-OVAR 2.2, 221t; OV-10, 85t; OV16, 143t; OVA-301, 237; paclitaxel, 206t; paclitaxel + carboplatin (TC), 78t, 94t, 104t, 143t, 248t; paclitaxel + cisplatin (TP), 78t, 85t, 104t; pegylated liposomal doxorubicin (PLD), 127, 231t; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; SCOTROC, 106, 108t, 109; topotecan, 206t; topotecan versus paclitaxel trial, 206t toxicity, neuropathy. See toxicity, neurotoxicity toxicity, neurotoxicity: AGO-OVAR/NCIC/EORTC trial, 227t; AGO-OVAR-3, 104t, 105, 223; AGO-OVAR/NCIC/EORTC trial, 228; AURELIA, 262; CALYPSO, 244, 246, 248t; carboplatin, 94t, 227t; carboplatin + gemcitabine, 117t, 228; carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t, 248t; cisplatin, 73t, 75; cyclophosphamide + cisplatin (CP), 61t, 65t, 85t; cyclophosphamide + doxorubicin + cisplatin (CAP), 94t; cumulative, 243; Danish Netherlands Trial, 78t, 79; docetaxel + carboplatin, 108t; dose-dense paclitaxel + carboplatin, 125t; gemcitabine, 233t; gemcitabine versus PLD trial, 233t; GOG 97, 55; GOG 104, 63, 65t; GOG 111, 59, 61t, 85; GOG 114, 88, 89t; GOG 132, 71, 73t; GOG 152, 173; GOG 158, 97, 98t, 99; GOG 157, 41t, 194; GOG 172, 111, 112, 113t; GOG 175, 197, 198t; GOG 178/SWOG 9701, 188, 190t, 191, 192, 193; GOG 182/ICON5, 118t; GOG 218, 152; ICON3, 94t, 95; ICON4/AGO-OVAR 2.2, 221t, 222; intraperitoneal cisplatin-based chemotherapy, 65t, 89t, 113t; JGOG 3016, 121, 125t, 125; maintenance chemotherapy, 198t; maintenance paclitaxel, 190t, 191, 197; MITO-2, 128, 130t, 131; MITO-7, 158, 159, 160t, 161; OV-10, 82, 85, 85t; OV16, 140, 145t; paclitaxel, 73t, 206t; paclitaxel + carboplatin (TC), 41t, 78t, 79, 93, 94t, 98t, 104t, 108t, 118t, 125t, 130t, 145t, 57, 160t, 161, 243, 248t; paclitaxel + cisplatin (TP), 61t, 73t, 78t, 79, 85t, 85t, 98t, 104t, 113t, 170; pegylated liposomal doxorubicin (PLD), 233t; pegylated liposomal doxorubicin (PLD) + carboplatin, 127; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; SCOTROC, 106, 108t, 109; topotecan, 206t; topotecan versus paclitaxel trial, 206t; weekly paclitaxel + carboplatin, 160t toxicity, neutropenia: AGO-OVAR/NCIC/EORTC trial, 226t; AGO-OVAR/3, 104t; AGO-OVAR9, 136t; AGO-OVAR/NCIC/EORTC trial, 224; CALYPSO, 248t; carboplatin, 226t; carboplatin + gemcitabine, 224, 226t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 131t, 248t; CHORUS, 185t; cyclophosphamide + cisplatin (CP), 61t, 84t; docetaxel + carboplatin, 108t; dose-dense paclitaxel + carboplatin, 125t; Doxil Study 30–49, 210, 214t; gemcitabine, 231t, 233t; gemcitabine versus PLD trial, 230, 231t, 233t; GOG 104, 66; GOG 111, 6t; GOG 132, 71, 72; GOG 178/SWOG 9701, 188, 190t; GOG 182/ICON5, 118t; GOG 218, 152, 155t; JGOG 3016, 121, 125t, 161; maintenance paclitaxel, 190t; MITO-2, 131t; MITO-7, 158, 160t, 161; neoadjuvant chemotherapy, 185t; OCEANS, 252, 255; OV-10, 82, 84t; OV16, 139; OVA-301, 237, 240t, 241; paclitaxel, 206t; paclitaxel + carboplatin (TC), 104t, 108t, 118t, 125t,
toxicity, neutropenia (cont.)
13t, 136t, 155t, 160t, 161, 248t;
paclitaxel + carboplatin + bevacizumab
(PCB), 155t; paclitaxel + cisplatin (TP),
61t, 84t, 104t, 169; pegylated liposomal
doxorubicin (PLD), 214t, 231t, 233t, 240t;
p pegylated liposomal doxorubicin
(PLD) + carboplatin, 127; pegylated
liposomal doxorubicin (PLD) + trabectedin,
240t, 241; primary debulking surgery,
183t; SCOTROC, 106, 107, 108t;
topotecan, 206t, 210, 214t, 215; topotecan
versus paclitaxel trial, 203, 206t, 207;
weekly paclitaxel + carboplatin, 160t
toxicity, ototoxicity: AGO/OVAR-3, 104t;
cisplatin, 75; cyclophosphamide +
cisplatin (CP), 65t, 85t; GOG 97, 55;
GOG 104, 65t, 66; GOG 111, 59; GOG
132, 74; intraperitoneal cisplatin-based
chemotherapy, 65t; OV-10, 82, 85t;
paclitaxel + carboplatin (TC), 104t;
paclitaxel + cisplatin (TP), 85t, 104t,
170

toxicity, pain: GOG 158, 98t; GOG 172,
112, 113t; GOG 218, 155t, 156; intraperi-
toneal cisplatin-based chemotherapy,
113t; paclitaxel + carboplatin (TC), 98t,
155t; paclitaxel + carboplatin + bevaci-
zumab (PCB), 155t; paclitaxel + cisplatin
(TP), 98t, 113t
toxicity, palmar-plantar erythrodysesthesia
(PPE): AURELIA, 262; CALYPSO, 248,
248t; carboplatin + pegylated liposomal
doxorubicin (C-PLD), 127, 248t;
description, 216; dimethyl sulfoxide, 216;
Doxil study 30–49, 214t; dose modifica-
tions, 216; gemcitabine, 231t, 233t;
gemcitabine versus PLD trial, 231t, 233t,
234; OVA-301, 238, 241; OVA-301, 240t;
paclitaxel + carboplatin (TC), 248t;
p pegylated liposomal doxorubicin (PLD),
127, 208, 210, 214t, 215, 216, 231t, 233t,
234, 240t, 241; pegylated liposomal
doxorubicin + trabectedin, 240t;
pyridoxine, 216; treatment, 216;
topotecan, 214t
toxicity, peripheral edema: docetaxel +
carboplatin, 108t; SCOTROC, 108t
toxicity, platelet: AGO-OVAR, 136t;
AGO-OVAR/NCIC/ EORTC trial, 224;
AGO-OVAR, 136t; AGO-OVAR/NCIC/
EORTC trial, 224; CALYPSO, 248t;
carboplatin, 69t, 226t; carboplatin +
gemcitabine, 224, 226t; carboplatin +
pegylated liposomal doxorubicin
(C-PLD), 130t, 248t; cyclophosphamide +
cisplatin (CP), 56t, 61t, 65t; cyclophos-
phamide + doxorubicin (CA), 49t;
cyclophosphamide + doxorubicin +
cisplatin (CAP), 49t, 52t, 69t;
cyclophosphamide + cisplatin (CP), 18t,
52t, 85t; Danish Netherlands Trial, 78t;
docetaxel + carboplatin, 108t; dose-dense
paclitaxel + carboplatin, 125t; Doxil study
30–49, 214t; gemcitabine, 233t;
gemcitabine versus PLD trial, 230, 233t;
GOG 47, 47–48, 49t; GOG 52, 51; GOG
95, 18t; GOG 97, 56t; GOG 104, 65t;
GOG 111, 61t; GOG 114, 89t; GOG 132,
71, 74; GOG 158, 98t; GOG 172, 113t;
GOG 175, 196; GOG 178/SWOG 9701,
188; GOG 182/ICON5, 118t; ICON2, 69t;
intraperitoneal cisplatin-based chemotherapy, 65t, 89t, 113t; JGOG 3016, 121, 125t, 161; ICON2, 70; MITO-2, 130t; MITO-7, 158, 161; OCEANS, 252; OV-10, 82, 85t; OVI6, 139, 143t; OVA-301, 237; paclitaxel, 260t; paclitaxel + carboplatin (TC), 78t, 89t, 104t, 108t, 118t, 125t, 130t, 136t, 143t, 161, 248t; paclitaxel + cisplatin (TP), 61t, 78t, 85t, 98t, 104t, 113t, 169; pegylated liposomal doxorubicin (PLD), 214t, 233t; SCOTROC, 107, 108t; topotecan, 206t, 214t; topotecan versus paclitaxel trial, 206t, 207
toxicity, posterior reversible encephalopa-
thy syndrome (PRES): GOG 218, 156t;
paclitaxel + carboplatin (TC), 156t;
paclitaxel + carboplatin + bevacizumab
(PCB), 156t
toxicity, proteinuria: AURELIA, 261t, 262;
bevacizumab, 153; chemotherapy alone,
261t; chemotherapy + bevacizumab, 261t;
GOG 218, 153, 155t, 156; carboplatin +
gemcitabine, 254t; carboplatin + gem-
icitabine + bevacizumab, 254t; OCEANS,
254t, 255; paclitaxel + carboplatin (TC),
155t; paclitaxel + carboplatin + bevac-
zumab (PCB), 155t
Index

321
toxicity, pulmonary: cyclophosphamide + cisplatin (CP), 65t; Danish Netherlands Trial, 79; GOG 104, 65t; GOG 182/ICON5, 118t; intraperitoneal cisplatin-based chemotherapy, 65t; MITO-7, 160t; paclitaxel + carboplatin (TC), 118t, 160t; weekly paclitaxel + carboplatin, 160t
toxicity, renal: AGO/OVAR-3, 104t; cisplatin, 18t, 56t, 61t; cyclophosphamide + cisplatin (CP), 18t, 56t, 61t; Danish Netherlands Trial, 79; GOG 95, 18t; GOG 97, 55, 56t; GOG 104, 63; GOG 111, 59, 61t; GOG 132, 71, 73t, 74; GOG 158, 97; GOG 172, 111, 113t; ICON4/AGO-OVAR 2.2, 221t; intraperitoneal 32P, 18t; intraperitoneal cisplatin-based chemotherapy, 113t; MITO-2, 128; OV-10, 82, 82t, 140; paclitaxel, 73t; paclitaxel + carboplatin, 104t; paclitaxel + cisplatin (TP), 61t, 73t, 104t, 113t, 170; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; topotecan, 210
toxicity, reversible posterior leukoencephalopathy syndrome (RPLS): bevacizumab, 153; carboplatin + gemcitabine, 254t; carboplatin + gemcitabine + bevacizumab, 254t; GOG 218, 153; OCEANS, 254t, 255
toxicity, RPLS. See toxicity, reversible posterior leukoencephalopathy syndrome
toxicity, secondary malignancy: GOG 175, 198t; maintenance chemotherapy, 198t
toxicity, sepsis: Doxil study 30–49, 214t; paclitaxel, 206t; pegylated liposomal doxorubicin (PLD), 214t; topotecan, 206t, 214t; topotecan versus paclitaxel trial, 206t
toxicity, skin: carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t; Danish Netherlands Trial, 79; gemcitabine, 233t; gemcitabine versus PLD trial, 233t; GOG 175, 197, 198t; maintenance chemotherapy, 198t; MITO-2, 128, 130t, 131; paclitaxel + carboplatin (TC), 130t; pegylated liposomal doxorubicin (PLD), 116, 127, 208, 233t; SCOTROC, 107
toxicity, stomatitis: carboplatin + pegylated liposomal doxorubicin (C-PLD), 130t; cyclophosphamide + cisplatin (CP), 85t; Doxil study 30–49, 214t; MITO-2, 130t; OV-10, 85t; OVA-301, 238, 240t; paclitaxel + carboplatin (TC), 130t; paclitaxel + cisplatin (TP), 85t; pegylated liposomal doxorubicin (PLD), 127, 208, 210, 214t, 215, 240t; pegylated liposomal doxorubicin + trabectedin, 240t; topotecan, 214t
toxicity, thrombocytopenia. See toxicity, platelet
toxicity, thromboembolism: AURELIA, 261t; bevacizumab, 153; chemotherapy alone, 261t; chemotherapy + bevacizumab, 261t; GOG 218, 153, 155t; ICON7, 150t; OV16, 143t; paclitaxel + carboplatin (TC), 143t, 150t, 155t; paclitaxel + carboplatin + bevacizumab (PCB), 150t, 155t
toxicity, tinnitus: cyclophosphamide + cisplatin (CP), 65t; GOG 104, 65t, 66; GOG 132, 71; intraperitoneal cisplatin-based chemotherapy, 65t; paclitaxel + cisplatin (TP), 170
toxicity, venous thrombosis. See toxicity, thromboembolism
toxicity, vomiting: AGO/OVAR-3, 104t; CALYPSO, 248, 248t; carboplatin, 69t, 94t; carboplatin + pegylated liposomal doxorubicin (C-PLD), 248t; cisplatin, 13t, 14t; cyclophosphamide + cisplatin (CP), 52t, 56t, 85t; cyclophosphamide + doxorubicin + cisplatin (CAP), 52t, 69t, 94t; doxorubicin, 208; gemcitabine, 231t; gemcitabine versus PLD trial, 231t; GICOG trials, 13t, 14t; GOG 97, 56t; ICON2, 69t, 70; ICON3, 94t; ICON4/AGO-OVAR 2.2, 221t; MITO-7, 161; OV-10, 85t; OV16, 145t; OVA-301, 237; paclitaxel, 206t; paclitaxel + carboplatin (TC), 94t, 104t, 145t, 161, 248t; paclitaxel + cisplatin (TP), 85t, 104t; pegylated liposomal doxorubicin (PLD), 127, 231t; platinum chemotherapy, 221t; platinum + paclitaxel, 221t; topotecan, 206t; topotecan versus paclitaxel trial, 206t
toxicity, wound disruption: bevacizumab, 153, 156; GOG 218, 153, 156, 156t; paclitaxel + carboplatin (TC), 156t; paclitaxel + carboplatin + bevacizumab (PCB), 156t
toxicity assessments: GICOG trials, 12; GOG 111, 59; GOG 157, 39; SCOTROC, 107
toxicity bowel obstruction: GOG 7602, 8t; intraperitoneal technetium 99m, 8t
TP. See paclitaxel + cisplatin
trabectedin: activity in ovarian cancer, 236; dosing, 237; Ecteinascidia turbinata, 235; mechanism of antineoplastic effect, 235; OVA-310, 235–242; synergy with pegylated liposomal doxorubicin, 236; transcription-coupled nucleotide excision repair, 235
transcription-coupled nucleotide excision repair, 235
transfusion, blood: Doxil study 30–49, 214t; topotecan versus paclitaxel trial, 206t
transfusion, platelets, topotecan versus paclitaxel trial, 206t
treatment discontinuation: AGO-OVAR-3, 102; AGO-OVAR9, 134; AURELIA, 259; Doxil Study 30–49, 210; GOG 97, 55; GOG 104, 63; GOG 111, 59; GOG 152, 170; GOG 158, 97; GOG 178/SWOG 9701, 188; GOG 218, 152; MITO-2, 128; topotecan versus paclitaxel trial, 203
treatment modifications: GOG 97, 54, 57; GOG 111, 59; GOG 157, 39; GOG 158, 96–97; OV-10, 82
treosulfan, 234
tumor kinetics, 137
tumor size, prognostic impact, 79, 173, 178
ultra-radical procedures, CHORUS, 181
ultrasound: AGO/OVAR-3, 103; GICOG trials, 12; topotecan versus paclitaxel study, 202
vascular endothelial growth factor (VEGF), 145, 151, 249, 257
venous thromboembolism. See toxicity, thromboembolism
ventricular irritability, 60
vinorelbine, response rates, 215
vomiting. See toxicity, vomiting
weekly paclitaxel. See dose-dense paclitaxel
whole abdominal radiation, 20
Wilcoxon Mann-Whitney test, AGO-OVAR9, 135
Wilcoxon rank-sum test: CALYPSO, 246; GOG 172, 112; OV16, 142
World Health Organization, response criteria: CHORUS, 181; EORTC 55971, 175; EORTC-GCG 55865, 165; topotecan versus paclitaxel trial, 203
World Health Organization toxicity assessment, GICOG trials, 12
wound disruption. See toxicity, wound disruption
X-ray: AGO/OVAR-3, 103; Doxil Study 30–49, 209
Zelens exact test, AGO-OVAR9, 135